NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Cervical Cancer

Version 1.2014

NCCN.org
### NCCN Guidelines Panel Members

<table>
<thead>
<tr>
<th>Cervical Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Wui-Jin Koh, MD/Co-Chair §</strong></td>
</tr>
<tr>
<td>Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance</td>
</tr>
<tr>
<td><strong>Benjamin E. Greer, MD/Co-Chair Ω</strong></td>
</tr>
<tr>
<td>Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance</td>
</tr>
<tr>
<td><strong>Nadeem R. Abu-Rustum, MD Ω</strong></td>
</tr>
<tr>
<td>Memorial Sloan-Kettering Cancer Center</td>
</tr>
<tr>
<td><strong>Sachin M. Apte, MD, MS Ω</strong></td>
</tr>
<tr>
<td>Moffitt Cancer Center</td>
</tr>
<tr>
<td><strong>Susana M. Campos, MD, MPH, MS †</strong></td>
</tr>
<tr>
<td>Dana-Farber/Brigham and Women’s Cancer Center</td>
</tr>
<tr>
<td><strong>Kathleen R. Cho, MD ≠</strong></td>
</tr>
<tr>
<td>University of Michigan Comprehensive Cancer Center</td>
</tr>
<tr>
<td><strong>David Cohn, MD Ω</strong></td>
</tr>
<tr>
<td>The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute</td>
</tr>
<tr>
<td><strong>Marta Ann Crispens, MD Ω</strong></td>
</tr>
<tr>
<td>Vanderbilt-Ingram Cancer Center</td>
</tr>
<tr>
<td><strong>Nefertiti DuPont, MD, MPH Ω</strong></td>
</tr>
<tr>
<td>Roswell Park Cancer Institute</td>
</tr>
<tr>
<td><strong>Patricia J. Eifel, MD §</strong></td>
</tr>
<tr>
<td>The University of Texas MD Anderson Cancer Center</td>
</tr>
<tr>
<td><strong>Christine M. Fisher, MD, MPH §</strong></td>
</tr>
<tr>
<td>University of Colorado Cancer Center</td>
</tr>
<tr>
<td><strong>David K. Gaffney, MD, PhD §</strong></td>
</tr>
<tr>
<td>Huntsman Cancer Institute at the University of Utah</td>
</tr>
<tr>
<td><strong>Ernest Han, MD, PhD Ω</strong></td>
</tr>
<tr>
<td>City of Hope Comprehensive Cancer Center</td>
</tr>
<tr>
<td><strong>Warner K. Huh, MD Ω</strong></td>
</tr>
<tr>
<td>University of Alabama at Birmingham Comprehensive Cancer Center</td>
</tr>
<tr>
<td><strong>John R. Lurain, III, MD Ω</strong></td>
</tr>
<tr>
<td>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</td>
</tr>
<tr>
<td><strong>Lainie Martin, MD †</strong></td>
</tr>
<tr>
<td>Fox Chase Cancer Center</td>
</tr>
<tr>
<td><strong>David Mutch, MD Ω</strong></td>
</tr>
<tr>
<td>Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</td>
</tr>
<tr>
<td><strong>Amanda Nickles Fader, MD Ω</strong></td>
</tr>
<tr>
<td>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</td>
</tr>
<tr>
<td><strong>Steven W. Remmenga, MD Ω</strong></td>
</tr>
<tr>
<td>Fred &amp; Pamela Buffet Cancer Center at The Nebraska Medical Center</td>
</tr>
<tr>
<td><strong>R. Kevin Reynolds, MD Ω</strong></td>
</tr>
<tr>
<td>University of Michigan Comprehensive Cancer Center</td>
</tr>
<tr>
<td><strong>William Small, Jr., MD §</strong></td>
</tr>
<tr>
<td>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</td>
</tr>
<tr>
<td><strong>Nelson Teng, MD, PhD Ω</strong></td>
</tr>
<tr>
<td>Stanford Cancer Institute</td>
</tr>
<tr>
<td><strong>Todd Tillmanns, MD Ω</strong></td>
</tr>
<tr>
<td>St. Jude Children’s Research Hospital/University of Tennessee Health Science Center</td>
</tr>
<tr>
<td><strong>Fidel A. Valea, MD Ω</strong></td>
</tr>
<tr>
<td>Duke Cancer Institute</td>
</tr>
<tr>
<td><strong>Catheryn M. Yashar, MD §</strong></td>
</tr>
<tr>
<td>UC San Diego Moores Cancer Center</td>
</tr>
</tbody>
</table>

---

**NCCN Guidelines Panel Disclosures**

Ω Gynecologic oncology  
† Medical oncology  
§ Radiotherapy/Radiation oncology  
≠ Pathology  
* Writing committee member

---

Version 1.2014, 02/25/14 © National Comprehensive Cancer Network, Inc. 2014, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
Principles of Evaluation and Surgical Staging

Nadeem R. Abu-Rustum, MD Ω/Lead
Memorial Sloan-Kettering Cancer Center

R. Kevin Reynolds, MD Ω
University of Michigan
Comprehensive Cancer Center
The NCCN Guidelines for Cervical Cancer include the management of squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix.

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2014.
Updates in Version 1.2014 of the NCCN Guidelines for Cervical Cancer from Version 3.2013 include:

Global Changes:
• “Principles of Evaluation and Surgical Staging” is a new section that provides recommendations and techniques for surgical staging, sentinel lymph node mapping, and surgical evaluation for cervical cancer. (CERV-A)

CERV-1
• Workup:
  ‣ Seventh bullet changed to “Smoking cessation and counseling intervention if indicated.” Previously it was listed as optional for ≥ stage IB2.
  ‣ Consider HIV testing was added as a category 3 recommendation.

CERV-2
• Stage IA1 (with LVSI) and Stage IA2; Primary treatment (fertility sparing): Recommendations were revised as follows:
  ‣ “Cone biopsy with negative margins (preferably a non-fragmented specimen with 3-mm negative margins if positive margins, repeat cone biopsy or perform tracheectomy) + pelvic lymph node dissection ± para-aortic lymph node sampling (category 2B) (Consider sentinel lymph node mapping [category 2B])” or
  ‣ Radical tracheectomy + pelvic lymph node dissection (± para-aortic lymph node sampling [category 2B]) (Consider sentinel lymph node mapping [category 2B])

• Stage IB1; Primary treatment (fertility sparing): Recommendation revised “Radical tracheectomy + pelvic lymph node dissection ± para-aortic lymph node sampling (Consider sentinel lymph node mapping [category 2B])”

• Footnote “c” was revised: “Fertility-sparing surgery for stage IB1 has been most validated for tumors ≤2 cm. Small cell neuroendocrine histology and adenoma malignum are not considered suitable tumors for this procedure.”

• Footnote “e” is new to the algorithm: “Cold knife conization (CKC) is the preferred method of diagnostic excision, but LEEP is acceptable, provided adequate margins and proper orientation are obtained.”

• Footnote “g” is new to the algorithm: “For sentinel lymph node (SLN) mapping (category 2B), the best detection rates and mapping results are in tumors <2 cm.

CERV-3
• Stage IA1 (no LVSI); Cone biopsy; Positive margins for dysplasia or carcinoma; Primary treatment (non-fertility sparing):
  ‣ Recommendation revised, “Extracapsular or modified radical hysterectomy + pelvic lymph node dissection (category 2B for node dissection) (Consider sentinel lymph node mapping [category 2B])”
  ‣ “Consider repeat cone biopsy to better evaluate depth of invasion” was added as an option.

• Stage IA1 (with LVSI) and Stage IA2; Primary treatment (non-fertility sparing): Recommendation revised, “Modified radical hysterectomy + pelvic lymph node dissection ± para-aortic lymph node sampling (consider sentinel lymph node mapping [category 2B]).”

CERV-4
• Stage IB1 and Stage IIA1; Primary treatment (non-fertility sparing): Recommendation revised, “Radical hysterectomy + pelvic lymph node dissection ± para-aortic lymph node sampling (category 1 for primary surgery) (Consider sentinel lymph node mapping [category 2B])."

• Stage IB2 and Stage IIA2; Primary treatment (non-fertility sparing): Recommendation revised, “Definitive pelvic RT + concurrent cisplatin-containing chemotherapy + brachytherapy (total point A dose ≥85 Gy)” (category 1 for primary chemoradiation).

CERV-5
• Surgical findings: “Negative nodes” modified to “Negative nodes, negative margins, negative parametrium.”

CERV-6
• Stage IB2, Stage IIA2; Primary treatment: The recommendation was clarified:
  “Pelvic RT + concurrent cisplatin-containing chemotherapy (category 1) + brachytherapy (category 1)” (Also for CERV-7 and CERV-8)
NCCN Guidelines Version 1.2014 Updates
Cervical Cancer

CERV-7
• IB2, IIA2; Stage IIB, IIA, IIB, IVA; Para-aortic lymph node positive by surgical staging; “Negative” pathways; Primary treatment: “Pelvic RT+ para-aortic lymph node RT + concurrent cisplatin-containing chemotherapy + brachytherapy” changed to “Extended-field RT + concurrent cisplatin-containing chemotherapy + brachytherapy.”

CERV-9
• Column headings revised for clarity: “Incidental Finding of Invasive Cancer After Simple Hysterectomy” and “Primary Treatment.”

CERV-10
• Surveillance: Last bullet revised, “Patient education regarding symptoms of potential recurrence.”
• Footnote “r” revised: “A single PET-CT scan performed at 3-6 months after chemoradiation for locally advanced cervical cancer can be used to identify suspect early or asymptomatic persistence/recurrence. Other imaging studies (such as chest x-ray, CT scan, MRI, and subsequent PET-CT) may also be used to assess or follow recurrence when clinically indicated but are not recommended for routine surveillance. (See Discussion). Recurrences should be proven by biopsy before proceeding to treatment planning.”

CERV-11
• Local/regional recurrence; Prior RT; Noncentral disease; Therapy for relapse: Recommendation clarified, “Resection with IORT for close or positive margins (category 3 for IORT).”

CERV-12
• The pathway for “Distant metastases” was revised extensively including:
  ▶ “Resectable” pathway changed to “Amenable to local treatment.” For these patients, under “Therapy for Relapse,” the recommendations were revised, “Consider resection ± IORT (category 3) or RT ± concurrent chemotherapy or Chemotherapy” changed to:
    ◊ “Local treatment:
      – Resection ± RT or Local ablative therapies ± RT or RT ± concurrent chemotherapy
      – May consider systemic adjuvant chemotherapy.”
  ▶ “Multiple sites or Unresectable” pathway changed to “Not amenable to local treatment.” For these patients, “Clinical trial” was added as an option under “Therapy for Relapse.”

CERV-B--Principles of Radiation Therapy for Cervical Cancer
Page 2 of 4
• Brachytherapy:
  ▶ First bullet revised: “...delivered using ovoids, ring, or cylinder brachytherapy (combined with the intrauterine tandem). MRI imaging immediately preceding brachytherapy may be helpful in delineating residual tumor geometry. When combined with EBRT...”
  ▶ Second bullet revised: “In rare cases, patients whose anatomy or tumor geometry renders intracavitary brachytherapy infeasible...”
  ▶ Third bullet revised: “In selected post-hysterectomy patients (especially those with positive or close vaginal mucosal surgical margins), vaginal cylinder brachytherapy may be used as a boost to EBRT.
  ▶ Last bullet was added: “Stereotactic body radiotherapy (SBRT) is not considered an appropriate routine alternative to brachytherapy.”
WORKUP

- H&P
- Complete blood count (CBC) (including platelets)
- Cervical biopsy, pathologic review
- Cone biopsy as indicated
- LFT/renal function studies
- Imaging
- (optional for ≤ stage IB1):
  - Chest x-ray
  - CT or PET-CT scan
  - MRI as indicated
- Smoking cessation and counseling intervention if indicated
- Consider HIV testing (category 3)
  Optional:
  - EUA cystoscopy/proctoscopy (≥ stage IB2)

CLINICAL STAGE

Stage IA1

Stage IA2
Stage IB1

Stage IIA1

Stage IB2
Stage IIA2

Stage IIB
Stage IIIA, IIIB
Stage IVA

Incidental finding of invasive cancer at simple hysterectomy

See Primary Treatment (Fertility Sparing) (CERV-2)

See Primary Treatment (Non-Fertility Sparing) (CERV-3)

See Primary Treatment (Fertility Sparing) (CERV-2)

See Primary Treatment (Non-Fertility Sparing) (CERV-3) and (CERV-4)

See Primary Treatment (Non-Fertility Sparing) (CERV-4)

See Primary Treatment (CERV-4) and (CERV-6)

See Primary Treatment (CERV-6)

See Treatment (CERV-9)

All staging in guideline is based on updated 2010 FIGO staging. (See ST-1)

---

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### CLINICAL STAGE

<table>
<thead>
<tr>
<th>Stage IA1 (no lymphovascular space invasion [LVS])</th>
<th>PRIMARY TREATMENT (FERTILITY SPARING)⁴&lt;sup&gt;d&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cone biopsy&lt;sup&gt;e&lt;/sup&gt; with negative margins (preferably a non-fragmented specimen with 3-mm negative margins) (If positive margins, repeat cone biopsy or perform trachelectomy)</td>
<td>See Surveillance (CERV-10)</td>
</tr>
</tbody>
</table>

| Stage IA1 (with LVS) and Stage IA2 | Cone biopsy<sup>e</sup> with negative margins (preferably a non-fragmented specimen with 3-mm negative margins-if positive margins, repeat cone biopsy or perform trachelectomy) + pelvic lymph node dissection ± para-aortic lymph node sampling (category 2B) (Consider sentinel lymph node mapping [category 2B])<sup>f</sup> or Radical trachelectomy + pelvic lymph node dissection<sup>f</sup> (± para-aortic lymph node sampling [category 2B]) (Consider sentinel lymph node mapping [category 2B])<sup>f</sup> | See Surveillance (CERV-10) |

| Stage IB<sup>c</sup> | Radical trachelectomy + pelvic lymph node dissection<sup>f</sup> ± para-aortic lymph node sampling (Consider sentinel lymph node mapping [category 2B])<sup>f,g</sup> | See Surveillance (CERV-10) |

<sup>c</sup>Fertility-sparing surgery for stage IB1 has been most validated for tumors ≤2 cm. Small cell neuroendocrine histology and adenoma malignum are not considered suitable tumors for this procedure.

<sup>d</sup>No data support a fertility-sparing approach in small cell neuroendocrine tumors or minimal deviation adenocarcinoma (also known as adenoma malignum). Total hysterectomy after completion of childbearing is at the patient's and surgeon's discretion, but is strongly advised in women with continued abnormal pap smears or chronic persistent HPV infection.

<sup>e</sup>Cold knife conization (CKC) is the preferred method of diagnostic excision, but LEEP is acceptable, provided adequate margins and proper orientation are obtained.

<sup>f</sup>See Principles of Evaluation and Surgical Staging (CERV-A).

<sup>g</sup>For SLN mapping (category 2B), the best detection rates and mapping results are in tumors <2 cm.

---

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
<table>
<thead>
<tr>
<th>CLINICAL STAGE</th>
<th>BIOPSY RESULTS</th>
<th>PRIMARY TREATMENT (NON-FERTILITY SPARING)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage IA1 (no LVSI)</td>
<td><strong>Cone biopsy</strong>&lt;sup&gt;e&lt;/sup&gt;</td>
<td><strong>Observe</strong></td>
</tr>
<tr>
<td></td>
<td>Negative margins and inoperable</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Negative margins and operable</td>
<td><strong>Extrافascular hysterectomy</strong>&lt;sup&gt;f&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Positive margins for dysplasia or carcinoma</td>
<td><strong>Extrافascular or modified radical hysterectomy</strong>&lt;sup&gt;f&lt;/sup&gt; + pelvic lymph node dissection&lt;sup&gt;f&lt;/sup&gt; (category 2B for node dissection) (Consider sentinel lymph node mapping [category 2B])&lt;sup&gt;f&lt;/sup&gt; or Consider repeat cone biopsy&lt;sup&gt;e&lt;/sup&gt; to better evaluate depth of invasion</td>
</tr>
<tr>
<td>Stage IA1 (with LVSI) and Stage IA2</td>
<td></td>
<td><strong>Modified radical hysterectomy</strong> + pelvic lymph node dissection&lt;sup&gt;f&lt;/sup&gt; ± para-aortic lymph node sampling (category 2B) (Consider sentinel lymph node mapping [category 2B])&lt;sup&gt;f&lt;/sup&gt; or Pelvic RT&lt;sup&gt;h,i&lt;/sup&gt; + brachytherapy (total point A dose: 70-80 Gy)&lt;sup&gt;j&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>e</sup>Cold knife conization (CKC) is the preferred method of diagnostic excision, but LEEP is acceptable, provided adequate margins and proper orientation are obtained.

<sup>f</sup>See Principles of Evaluation and Surgical Staging (CERV-A).

<sup>h</sup>Radiation can be an option for medically inoperable patients or those who refuse surgery.

<sup>i</sup>See Principles of Radiation Therapy for Cervical Cancer (CERV-B).

<sup>j</sup>These doses are recommended for most patients based on summation of conventional external-beam fractionation and low-dose rate (40-70 cGy/h) brachytherapy equivalents. Modify treatment based on normal tissue tolerance. (See Discussion)

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
# Cervical Cancer

## CLINICAL STAGE

<table>
<thead>
<tr>
<th>Stage IB1 and Stage IIA1</th>
<th>PRIMARY TREATMENT (NON-FERTILITY SPARING)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Radical hysterectomy + pelvic lymph node dissection + para-aortic lymph node sampling (category 1 for primary surgery) (Consider sentinel lymph node mapping [category 2B]) or Pelvic RT + brachytherapy (total point A dose: 80-85 Gy) + concurrent cisplatin-containing chemotherapy (category 1 for primary surgery) or Pelvic RT + brachytherapy (total point A dose ≥85 Gy) (category 1 for primary chemoradiation) or Radical hysterectomy + pelvic lymph node dissection + para-aortic lymph node sampling (category 2B) or Pelvic RT + concurrent cisplatin-containing chemotherapy + brachytherapy (total point A dose 75-80 Gy) + adjuvant hysterectomy (category 3)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage IB2 and Stage IIA2 (also see CERV-6 for alternative recommendations for these patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definitive pelvic RT + concurrent cisplatin-containing chemotherapy + brachytherapy (total point A dose ≥85 Gy) (category 1 for primary chemoradiation) or Radical hysterectomy + pelvic lymph node dissection + para-aortic lymph node sampling (category 2B) or Pelvic RT + concurrent cisplatin-containing chemotherapy + brachytherapy (total point A dose 75-80 Gy) + adjuvant hysterectomy (category 3)</td>
</tr>
</tbody>
</table>

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

2. See Principles of Radiation Therapy for Cervical Cancer (CERV-B).
4. For SLN mapping (category 2B), the best detection rates and mapping results are in tumors <2 cm.
5. Radiation can be an option for medically inoperable patients or those who refuse surgery.
6. These doses are recommended for most patients based on summation of conventional external-beam fractionation and low-dose rate (40-70 cGy/h) brachytherapy equivalents. Modify treatment based on normal tissue tolerance. (See Discussion)
7. Concurrent cisplatin-based chemotherapy with RT utilizes cisplatin as a single agent or cisplatin plus 5-fluorouracil.
SURGICAL FINDINGS

### ADJUVANT TREATMENT

<table>
<thead>
<tr>
<th>Negative nodes, negative margins, negative parametrium</th>
<th>Observe or Pelvic RT(^i) if combination of high-risk factors (category 1) (i.e., large primary tumor, deep stromal invasion, and/or LVSI) ± concurrent cisplatin-based chemotherapy(^k) (category 2B for chemotherapy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive pelvic nodes and/or Positive surgical margin and/or Positive parametrium</td>
<td>Pelvic RT(^i) + concurrent cisplatin-containing chemotherapy(^k) (category 1) ± vaginal brachytherapy(^i)</td>
</tr>
<tr>
<td>Para-aortic lymph node positive by surgical staging</td>
<td>Chest CT or PET-CT scan</td>
</tr>
<tr>
<td>Positive for distant metastasis</td>
<td>Consider biopsy of suspicious areas as indicated</td>
</tr>
<tr>
<td>Negative for distant metastasis</td>
<td>Para-aortic lymph node RT(^i) + concurrent cisplatin-containing chemotherapy(^k) + pelvic RT(^i) ± brachytherapy(^i)</td>
</tr>
<tr>
<td>Positive for distant metastasis</td>
<td>Systemic therapy(^l) ± individualized RT(^i)</td>
</tr>
</tbody>
</table>

\(^i\)See Principles of Radiation Therapy for Cervical Cancer (CERV-B).

\(^k\)Concurrent cisplatin-based chemotherapy with RT utilizes cisplatin as a single agent or cisplatin plus 5-fluorouracil.

\(^l\)See Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer (CERV-C).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

See Surveillance (CERV-10)
**NCCN Guidelines Version 1.2014**

**Cervical Cancer**

### CLINICAL STAGE

#### ADDITIONAL WORKUP

- **Negative adenopathy**
  - Pelvic RT\(^i\) + concurrent cisplatin-containing chemotherapy\(^k\) + brachytherapy\(^l\)
    - (category 1)

- **Positive adenopathy**
  - Consider needle biopsy
    - See Imaging Results (CERV-8)

#### PRIMARY TREATMENT

- **Radiologic imaging only**
  - See Surveillance (CERV-10)

- **Surgical staging (category 2B): Extraperitoneal or laparoscopic lymph node dissection**
  - **Negative**
    - Pelvic RT\(^i\) + concurrent cisplatin-containing chemotherapy\(^k\) + brachytherapy\(^l\)
      - (category 1)
  - **Positive**
    - See Node Status (CERV-7)

---

1See Principles of Radiation Therapy for Cervical Cancer (CERV-B).

2Concurrent cisplatin-based chemotherapy with RT utilizes cisplatin as a single agent or cisplatin plus 5-fluorouracil.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Stage IB2, IIA2; Stage IIB, IIIA, IIIB, IVA

**NODE STATUS**

- **Pelvic lymph node positive and para-aortic lymph node negative by surgical staging**
  - Pelvic RT\(^i\) + concurrent cisplatin-containing chemotherapy\(^k\) + brachytherapy\(^i\) (category 1)

- **Para-aortic lymph node positive by surgical staging**
  - Further radiologic workup as clinically indicated
    - Negative for distant metastasis
      - Negative for distant metastasis
        - Consider biopsy of suspicious areas as indicated
          - Positive
            - Systemic therapy\(^m\) ± individualized RT\(^i\)
          - Negative
            - Positive
              - Systemic therapy\(^m\) ± individualized RT\(^i\)

\(^i\)See Principles of Radiation Therapy for Cervical Cancer (CERV-B).

\(^k\)Concurrent cisplatin-based chemotherapy with RT utilizes cisplatin as a single agent or cisplatin plus 5-fluorouracil.

\(^m\)See Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer (CERV-C).

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
NCCN Guidelines Version 1.2014
Cervical Cancer

Stage IB2, IIA2
Stage IIB, IIIA, IIIB, IVA

IMAGING RESULTS

<table>
<thead>
<tr>
<th>Pelvic node positive; Para-aortic lymph node negative</th>
<th>Pelvic RT\textsuperscript{i} + concurrent cisplatin-containing chemotherapy\textsuperscript{k} + brachytherapy\textsuperscript{i} (category 1) ± para-aortic lymph node RT\textsuperscript{i}</th>
<th>Pelvic RT\textsuperscript{i} + concurrent cisplatin-containing chemotherapy\textsuperscript{k} + brachytherapy\textsuperscript{i} (category 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>or</td>
<td>Extraperitoneal or laparoscopic lymph node dissection\textsuperscript{n}</td>
<td>or</td>
</tr>
<tr>
<td>Para-aortic negative</td>
<td>Para-aortic positive</td>
<td>Extended-field RT\textsuperscript{i} + concurrent cisplatin-containing chemotherapy\textsuperscript{k} + brachytherapy\textsuperscript{i}</td>
</tr>
</tbody>
</table>

| Pelvic node positive; Para-aortic lymph node positive | Consider extraperitoneal or laparoscopic lymph node dissection\textsuperscript{n} | Systemic therapy\textsuperscript{i} ± individualized RT\textsuperscript{i} |

Positive adenopathy by CT, MRI, and/or PET

Distant metastases; with biopsy confirmation as clinically indicated

\textsuperscript{1}See Principles of Radiation Therapy for Cervical Cancer (CERV-B).
\textsuperscript{k}Concurrent cisplatin-based chemotherapy with RT utilizes cisplatin as a single agent or cisplatin plus 5-fluorouracil.
\textsuperscript{\textsuperscript{2}}See Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer (CERV-C).
\textsuperscript{n}Consider postoperative imaging to confirm the adequacy of node removal.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

INCIDENTAL FINDING OF INVASIVE CANCER AFTER SIMPLE HYSTERECTOMY

Stage IA1 + Pathologic review + No LVSI

Pelvic RT\(^i\) + brachytherapy\(^j\) ± concurrent cisplatin-containing chemotherapy\(^k\)

See Surveillance (CERV-10)

Stage IA1 with LVSI or ≥ Stage IA2

• H&P
• CBC (including platelets)
• LFT/renal function studies
• Imaging (optional for ≤ stage IB1):
  › Chest x-ray
  › CT or PET-CT scan
  › MRI as indicated

Pelvic RT\(^i\)

Positve nodes

Pelvic RT\(^i\) (para-aortic lymph node RT if para-aortic lymph node positive) + concurrent cisplatin-containing chemotherapy\(^k\) ± individualized brachytherapy\(^l\) (if positive vaginal margin)

Positive nodes and/or
Positive surgical margin and/or
Positive parametrium

Imaging positive for nodal disease

Imaging negative for nodal disease

Consider surgical debulking of grossly enlarged nodes

Negative margins; negative imaging

Negative margins; gross residual disease, or positive imaging

Negative imaging

Imaging negative for nodal disease

Positive imaging

Positive imaging

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

\(^i\)See Principles of Radiation Therapy for Cervical Cancer (CERV-B).

\(^j\)Concurrent cisplatin-based chemotherapy with RT utilizes cisplatin as a single agent or cisplatin plus 5-fluorouracil.

\(^k\)Invasive cancer at surgical margin.
### Surveillance

- **Interval H&P**
  - every 3-6 mo for 2 y,
  - every 6-12 mo for 3-5 y,
  - then annually based on patient's risk of disease recurrence
- **Cervical/vaginal cytology annually**
  - as indicated for the detection of lower genital tract neoplasia
- **Imaging** (chest radiography, CT, PET, PET/CT, MRI) as indicated based on symptoms or examination findings suspicious for recurrence
- **Laboratory assessment** (CBC, blood urea nitrogen [BUN], creatinine) as indicated based on symptoms or examination findings suspicious for recurrence
- **Recommend use of vaginal dilator after RT**
- **Patient education regarding symptoms of potential recurrence**

### Workup

- **Persistent or recurrent disease**
  - **Additional imaging as clinically indicated**
  - **Surgical exploration in selected cases**

### Discussion

**See Therapy for Relapse (Local/regional recurrence) (CERV-11)**

**See Therapy for Relapse (Distant metastases) (CERV-12)**

---

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---


**q** Regular cytology can be considered for detection of lower genital tract dysplasia, although its value in detection of recurrent cervical cancer is limited. The likelihood of picking up asymptomatic recurrences by cytology alone is low.

**r** A single PET-CT scan performed at 3-6 months after chemoradiation for locally advanced cervical cancer can be used to suggest early or asymptomatic persistence/recurrence. Other imaging studies (such as chest x-ray, CT scan, MRI, and subsequent PET-CT) may also be used to assess or follow recurrence when clinically indicated but are not recommended for routine surveillance. (See Discussion). Recurrences should be proven by biopsy before proceeding to treatment planning.
**THERAPY FOR RELAPSE**

- **Local/Regional recurrence**
  - **No prior RT or failure outside of previously treated field**
    - Consider surgical resection, if feasible
    - Tumor-directed RT\(^i\) + platinum-based chemotherapy\(^k\) ± brachytherapy\(^i\)
    - Recurrence
    - Clinical trial or Chemotherapy\(^l\) or Best supportive care
  - **Pelvic exenteration ± intraoperative RT (IORT) (category 3 for IORT)**
    - In carefully selected patients with small (<2 cm) lesions
    - Radical hysterectomy or Brachytherapy\(^i\)
    - Recurrence
  - **Tumor-directed RT\(^i\) ± chemotherapy\(^i, k\)**
  - **Resection with IORT for close or positive margins (category 3 for IORT)**
  - **Clinical trial**
  - **Chemotherapy\(^l\)**
  - **Best supportive care (See NCCN Guidelines for Palliative Care)**

\(i\) See Principles of Radiation Therapy for Cervical Cancer (CERV-B).
\(k\) Concurrent cisplatin-based chemotherapy with RT utilizes cisplatin as a single agent or cisplatin plus 5-fluorouracil.
\(l\) See Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer (CERV-C).

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Distant metastases

Amenable to local treatment

• Local treatment:
  ‣ Resection ± RT
  or
  Local ablative therapies ± RT
  or
  RT± concurrent chemotherapy
  or
  May consider systemic adjuvant chemotherapy

Not amenable to local treatment

Clinical trial
or
Chemotherapy
or
Best supportive care
(See NCCN Guidelines for Palliative Care)

See Surveillance (CERV-10)

1See Principles of Radiation Therapy for Cervical Cancer (CERV-B).
2Concurrent cisplatin-based chemotherapy with RT utilizes cisplatin as a single agent or cisplatin plus 5-fluorouracil.
3See Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer (CERV-C).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Types of Resection and Appropriateness for Treatment of Cervical Cancer

- Treatment of cervical cancer is stratified by stage as delineated in the Guideline.
- Microinvasive disease, defined as FIGO stage IA-1 with no lymphovascular invasion (LVSI), has less than a 1% chance of lymphatic metastasis and may be managed conservatively with cone biopsy for preservation of fertility (with negative margins) or with simple hysterectomy when preservation of fertility is not desired or relevant. The intent of a cone biopsy is to remove the ectocervix and endocervical canal en bloc using a scalpel. This provides the pathologist with an intact, non-fragmented specimen without electrosurgical artifact, which facilitates margin status evaluation. If a loop electrosurgical excision procedure (LEEP) is chosen for treatment, the specimen should not be fragmented, and care must be undertaken to minimize electrosurgical artifact at the margins. The shape and depth of the cone biopsy may be tailored to the size, type, and location of the neoplastic lesion. For example, if there is concern for invasive adenocarcinoma versus adenocarcinoma in situ in the cervical canal, the cone biopsy would be designed as a narrow, long cone extending to the internal os in order not to miss possible invasion in the endocervical canal. Cone biopsy is indicated for triage and treatment of small cancers where there is no likelihood of cutting across gross neoplasm. In cases of stage IA1 with LVSI, a conization (with negative margins) with laparoscopic pelvic sentinel lymph node (SLN) mapping (category 2B for SLN)/lymphadenectomy is a reasonable strategy.

- Radical hysterectomy with bilateral pelvic lymph node dissection (with or without SLN mapping [category 2B for SLN]) is the preferred treatment for FIGO stage IA-2, IB, and IIA lesions when fertility preservation is not desired. Radical hysterectomy results in resection of much wider margins compared with a simple hysterectomy, including removal of parts of the cardinal and uterosacral ligaments and the upper 1-2 cm of the vagina; in addition, pelvic and sometimes para-aortic nodes are removed. Radical hysterectomy procedures may be performed either via laparotomy or laparoscopy, and the laparoscopy approach may be either with conventional or robotic techniques. The Querleu & Morrow classification system is a modern surgical classification that describes degree of resection and nerve preservation in 3-dimensional planes of resection. Procedural details for the most commonly used types of hysterectomy are described in Table 1 (see CERV-A 5 of 7).

- The radical vaginal trachelectomy with laparoscopic lymphadenectomy procedure (with or without SLN mapping [category 2B for SLN]) offers a fertility-sparing option for carefully selected individuals with stage IA-2 or stage IB-1 lesions of 2 cm diameter or less. The cervix, upper vagina, and supporting ligaments are removed as with a type B radical hysterectomy, but the uterine corpus is preserved. In the more than 300 subsequent pregnancies currently reported, there is a 10% likelihood of second trimester loss, but 72% of patients carry their gestation to 37 weeks or more. The abdominal radical trachelectomy has emerged as a reasonable fertility-sparing strategy. It provides larger resection of parametria than the vaginal approach, is suitable for select stage IB1 cases, and has been utilized in lesions up to 4 cm in diameter. The operation mimics a type C1 radical hysterectomy.
PRINCIPLES OF EVALUATION AND SURGICAL STAGING

Types of Resection and Appropriateness for Treatment of Cervical Cancer--continued

• Advanced-stage disease, including FIGO stage IIB and above, is not usually treated with hysterectomy, as delineated in the Guidelines. The majority of advanced-stage disease in the United States is treated with definitive chemoradiation. In some countries, select cases of stage IIB may be treated with upfront radical hysterectomy or neoadjuvant chemotherapy followed by radical hysterectomy.

• Recurrent or persistent disease in the central pelvis following radiation therapy may potentially be cured with the pelvic exenteration procedure. Preoperative assessment for exenteration is designed to identify or rule out distant metastasis. If the recurrence is confined to the pelvis, then surgical exploration is carried out. If intraoperative margin and node assessment are negative, then resection of pelvic viscera is completed. Depending on the location of the tumor, resection may include anterior exenteration, posterior exenteration, or total pelvic exenteration. In cases where the location of tumor allows adequate margins, the pelvic floor and anal sphincter may be preserved as a supra-levator exenteration. Table 2 summarizes the tissues typically removed with differing types of pelvic exenteration (See CERV-A 6 of 7). These are highly complex procedures and should be performed in centers with a high level of expertise for exenteration procedures. Primary pelvic exenteration (without prior pelvic radiation) is restricted to the rare case where pelvic radiation is contraindicated or to women who received prior pelvic radiation for another indication and then developed a metachronous, locally advanced cervical carcinoma and further radiation therapy is not feasible.
Sentinel Lymph Node Mapping for Cervical Cancer:

- SLN mapping as part of the surgical management of select stage I cervical cancer is considered in gynecologic oncology practices worldwide. While this technique has been used in tumors up to 4 cm in size, the best detection rates and mapping results are in tumors less than 2 cm.\(^8-11\) This simple technique utilized a direct cervical injection with dye or radiocolloid Technetium-99 (99Tc) into the cervix, usually at 2 or 4 points as shown in Figure 1 (below). The SLNs are identified at the time of surgery with direct visualization of colored dye, a fluorescent camera if indocyanine green (ICG) was used, or a gamma probe if 99Tc was used. SLNs following a cervical injection are commonly located medial to the external iliac vessels, ventral to the hypogastric vessels, or in the superior part of the obturator space (Figure 2). SLNs usually undergo ultrastaging by pathologists, which allows for higher detection of micrometastasis that may alter postoperative management.\(^2,12\)

\[\text{Figure 1: Options of SLN Cervical Injection Sites}\]

\[\text{Figure 2: SLNs (blue, arrow) After Cervical Injection Are Commonly Located Medial to the External Iliac, Ventral to the Hypogastric, or in the Superior Part of the Obturator Space}\]

\(\dagger\)Figures 1 and 2 are reproduced with permission from Memorial Sloan-Kettering Cancer Center. © 2013 Memorial Sloan-Kettering Cancer Center.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF EVALUATION AND SURGICAL STAGING WHEN SLN MAPPING IS USED

The key to a successful SLN mapping (category 2B) is the adherence to the SLN algorithm, which requires the performance of a side-specific nodal dissection in cases of failed mapping and removal of any suspicious or grossly enlarged nodes regardless of mapping (Figure 3).

Figure 3. Surgical/SLN Mapping Algorithm for Early-Stage Cervical Cancer

1. Excision of all mapped SLN
   (submit for ultrastaging if negative H&E)

2. Any suspicious nodes must be removed regardless of mapping

3. If there is no mapping on a hemi-pelvis, a side-specific LND is performed

4. Parametrectomy is performed en bloc with a resection of the primary tumor

H&E: Hematoxylin and eosin staining
LND: Lymphadenectomy
SLN: Sentinel lymph node

2Intracervical injection with dye, 99m technetium, or both.
3Including interiliac/subaortic nodes.
4Exceptions made for select cases (see CERV-A 1 of 7).

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### TABLE 1: Resection of cervical cancer as primary therapy.¹

<table>
<thead>
<tr>
<th>Indication</th>
<th>Simple Hysterectomy (Type I)</th>
<th>Modified Radical Hysterectomy (Type II)</th>
<th>Radical Hysterectomy (Type III)</th>
<th>Simple Trachelectomy</th>
<th>Radical Trachelectomy²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage IA-1</td>
<td>Stage IA-1</td>
<td>Local disease without obvious metastasis, including: Stage IB-1 and 2 Selected Stage IIA</td>
<td>HSIL and stage IA-1</td>
<td>Stage IA-2 and Stage IB-1 if ≤2 cm diameter and squamous histology</td>
<td></td>
</tr>
<tr>
<td>Stage IB-1 and 2</td>
<td>Curative for microinvasion</td>
<td>Curative for small lesions</td>
<td>Curative for larger lesions</td>
<td>Curative for microinvasion Fertility preserved</td>
<td></td>
</tr>
<tr>
<td>Stage IIA</td>
<td></td>
<td></td>
<td></td>
<td>Curative for select stage IB-1 and IA-2 Fertility preserved</td>
<td></td>
</tr>
<tr>
<td>HSIL and stage IA-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intent</th>
<th>Curative for microinvasion</th>
<th>Curative for small lesions</th>
<th>Curative for larger lesions</th>
<th>Curative for microinvasion Fertility preserved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Curative for select stage IB-1 and IA-2 Fertility preserved</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Uterus</th>
<th>Removed</th>
<th>Removed</th>
<th>Removed</th>
<th>Spared</th>
<th>Spared</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ovary</td>
<td>Optional removal</td>
<td>Optional removal</td>
<td>Optional removal</td>
<td>Spared</td>
<td>Spared</td>
</tr>
<tr>
<td>Cervix</td>
<td>Removed</td>
<td>Removed</td>
<td>Removed</td>
<td>Spared</td>
<td>Spared</td>
</tr>
<tr>
<td>Vaginal margin</td>
<td>None</td>
<td>1–2 cm margin</td>
<td>Upper 1/4 to 1/3 of vagina</td>
<td>None</td>
<td>Upper 1/4 to 1/3 of vagina</td>
</tr>
<tr>
<td>Ureters</td>
<td>Not mobilized</td>
<td>Tunneled through broad ligament</td>
<td>Tunneled through broad ligament</td>
<td>Not mobilized</td>
<td>Tunneled through broad ligament</td>
</tr>
<tr>
<td>Cardinal ligaments</td>
<td>Resected at uterine and cervical border</td>
<td>Divided where ureter transits the broad ligament</td>
<td>Divided at pelvic sidewall</td>
<td>Resected at cervical border</td>
<td>Divided at pelvic sidewall</td>
</tr>
<tr>
<td>Bladder</td>
<td>Mobilized to base of cervix</td>
<td>Mobilized to upper vagina</td>
<td>Mobilized to middle origin</td>
<td>Mobilized to peritoneal reflection</td>
<td>Mobilized to peritoneal reflection</td>
</tr>
<tr>
<td>Rectum</td>
<td>Not mobilized</td>
<td>Mobilized below cervix</td>
<td>Mobilized below middle vagina</td>
<td>Mobilized to peritoneal reflection</td>
<td>Mobilized to above peritoneal reflection</td>
</tr>
<tr>
<td>Surgical Approach</td>
<td>Laparotomy or laparoscopy</td>
<td>Laparotomy or laparoscopy or robotic laparoscopy</td>
<td>Laparotomy or laparoscopy or robotic laparoscopy</td>
<td>Vaginal</td>
<td>Vaginal or laparotomy or laparoscopy, or robotic laparoscopy</td>
</tr>
</tbody>
</table>


²Fertility-sparing radical trachelectomy is most validated for lesions ≤2 cm in diameter. Small cell neuroendocrine histology and adenoma malignum are not considered suitable tumors for this procedure.

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
TABLE 2: Resection of recurrent cervical cancer with no distant metastasis

<table>
<thead>
<tr>
<th></th>
<th>Comparison of Infra-levator Exenteration Types</th>
<th>Comparison of Supra-levator Exenteration Types</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Anterior</td>
<td>Posterior</td>
</tr>
<tr>
<td>Indication</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uterus, tubes, ovaries</td>
<td>Removed if still present</td>
<td>Removed if still present</td>
</tr>
<tr>
<td>Vagina</td>
<td>Removed</td>
<td>Removed</td>
</tr>
<tr>
<td>Bladder and urethra</td>
<td>Removed</td>
<td>Preserved</td>
</tr>
<tr>
<td>Rectum</td>
<td>Preserved</td>
<td>Removed</td>
</tr>
<tr>
<td>Anal sphincter</td>
<td>Preserved</td>
<td>Removed</td>
</tr>
<tr>
<td>Reconstruction options</td>
<td>Ileal conduit or Continent conduit</td>
<td>NA</td>
</tr>
<tr>
<td>Urinary system</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reconstruction options</td>
<td>NA</td>
<td>End colostomy</td>
</tr>
<tr>
<td>GI system</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vagina</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF EVALUATION AND SURGICAL STAGING
(References)


Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF RADIATION THERAPY FOR CERVICAL CANCER

External Beam Radiation Therapy (EBRT)

• The use of CT-based treatment planning and conformal blocking is considered the standard of care for EBRT. MRI is the best imaging modality for determining soft tissue and parametrial involvement in patients with advanced tumors. In patients who are not surgically staged, PET imaging is useful to help define the nodal volume of coverage.

• The volume of EBRT should cover the gross disease (if present), parametria, uterosacral ligaments, sufficient vaginal margin from the gross disease (at least 3 cm), presacral nodes, and other nodal volumes at risk. For patients with negative nodes on surgical or radiologic imaging, the radiation volume should include the entirety of the external iliac, internal iliac, and obturator nodal basins. For patients deemed at higher risk of lymph node involvement (eg, bulkier tumors; suspected or confirmed nodes confined to the low true pelvis), the radiation volume should be increased to cover the common iliacs as well. In patients with documented common iliac and/or para-aortic nodal involvement, extended-field pelvic and para-aortic radiotherapy is recommended, up to the level of the renal vessels (or even more cephalad as directed by involved nodal distribution).

• Coverage of microscopic nodal disease requires an EBRT dose of approximately 45 Gy (in conventional fractionation of 1.8-2.0 Gy daily), and highly conformal boosts of an additional 10-15 Gy may be considered for limited volumes of gross unresected adenopathy. For the majority of patients who receive EBRT for cervical cancer, concurrent cisplatin-based chemotherapy (either cisplatin alone, or cisplatin + 5-fluorouracil) is given during the time of EBRT.

• Intensity-modulated radiation therapy (IMRT) and similar highly conformal methods of dose delivery may be helpful in minimizing the dose to the bowel and other critical structures in the post-hysterectomy setting and in treating the para-aortic nodes when necessary. These techniques can also be useful when high doses are required to treat gross disease in regional lymph nodes. However, conformal external beam therapies (such as IMRT) should not be used as routine alternatives to brachytherapy for treatment of central disease in patients with an intact cervix. Very careful attention to detail and reproducibility (including consideration of target and normal tissue definitions, patient and internal organ motion, soft tissue deformation, and rigorous dosimetric and physics quality assurance) is required for proper delivery of IMRT and related highly conformal technologies.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF RADIATION THERAPY FOR CERVICAL CANCER

Brachytherapy

- Brachytherapy is a critical component of definitive therapy for all patients with primary cervical cancer who are not candidates for surgery. This is usually performed using an intracavitary approach, with an intrauterine tandem and vaginal colpostats. Depending on the patient and tumor anatomy, the vaginal component of brachytherapy in patients with an intact cervix may be delivered using ovoids, ring, or cylinder brachytherapy (combined with the intrauterine tandem). MRI imaging immediately preceding brachytherapy may be helpful in delineating residual tumor geometry. When combined with EBRT, brachytherapy is often initiated towards the latter part of treatment, when sufficient primary tumor regression has been noted to permit satisfactory brachytherapy apparatus geometry. In highly selected very early disease (ie, stage IA2), brachytherapy alone (without EBRT) may be an option.

- In rare cases, patients whose anatomy or tumor geometry renders intracavitary brachytherapy infeasible may be best treated using an interstitial approach; however, such interstitial brachytherapy should only be performed by individuals and at institutions with appropriate experience and expertise.

- In selected post-hysterectomy patients (especially those with positive or close vaginal mucosal surgical margins), vaginal cylinder brachytherapy may be used as a boost to EBRT.

- Stereotactic body radiotherapy (SBRT) is not considered an appropriate routine alternative to brachytherapy.

Radiation Dosing Considerations

- The most common historical dosing parameters for brachytherapy use a system that includes specifying the dose at point A and incorporates specific guidelines for “radioactive source loading and distribution of activity” within the uterus and vagina, based on anatomic considerations. Doses are also calculated at standardized point B and bladder and rectal points. Current efforts at 3-D image-guided brachytherapy seek to optimize implant dose coverage of the tumor, while potentially reducing the dose to adjacent bladder, rectum, and bowel structures. Nonetheless, the weight of experience and tumor control results and the majority of continuing clinical practice have been based on the point A dosing system. Attempts to improve dosing with image-guided brachytherapy should take care not to underdose tumors relative to the point A system dose recommendations.

- The point A dose recommendations provided in the NCCN Guidelines are based on traditional, and widely validated, dose fractionation and brachytherapy at low dose rates (LDRs). In these provided dose recommendations, for EBRT, the dose is delivered at 1.8-2.0 Gy per daily fraction. For brachytherapy, the dose at point A assumes an LDR delivery of 40 to 70 cGy/h. Clinicians using HDR brachytherapy would depend on the linear-quadratic model equation to convert nominal HDR dose to point A to a biologically equivalent LDR dose to point A (http://www.americanbrachytherapy.org/guidelines/). Multiple brachytherapy schemes have been used when combined with EBRT. However, one of the more common HDR approaches is 5 insertions with tandem and colpostats, each delivering 6 Gy nominal dose to point A. This scheme results in a nominal HDR point A dose of 30 Gy in 5 fractions, which is generally accepted to be the equivalent to 40 Gy to point A (tumor surrogate dose) using LDR brachytherapy.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF RADIATION THERAPY FOR CERVICAL CANCER

Definitive Radiation Therapy for an Intact Cervix
• In patients with an intact cervix (i.e., those who do not have surgery), the primary tumor and regional lymphatics at risk are typically treated with definitive EBRT to a dose of approximately 45 Gy (40-50 Gy). The volume of the EBRT would depend on the nodal status as determined surgically or radiographically (as previously described). The primary cervical tumor is then boosted, using brachytherapy, with an additional 30 to 40 Gy to point A (in LDR equivalent dose), for a total point A dose (as recommended in the guidelines) of 80 Gy (small volume cervical tumors) to 85 Gy or greater (larger volume cervical tumors). Grossly involved unresected nodes may be evaluated for boosting with an additional 10 to 15 Gy of highly conformal (and reduced volume) EBRT. With higher doses, especially of EBRT, care must be taken to exclude, or to severely limit, the volume of normal tissue included in the high-dose region(s) (see Discussion).

Posthysterectomy Adjuvant Radiation Therapy
• Following primary hysterectomy, the presence of one or more pathologic risk factors may warrant the use of adjuvant radiotherapy. At a minimum, the following should be covered: upper 3 to 4 cm of the vaginal cuff, the parametria, and immediately adjacent nodal basins (such as the external and internal iliacs). For documented nodal metastasis, the superior border of the radiation field should be appropriately increased (as previously described). A dose of 45 to 50 Gy in standard fractionation is generally recommended. Grossly involved unresected nodes may be evaluated for boosting with an additional 10 to 15 Gy of highly conformal (and reduced volume) EBRT. With higher doses, especially of EBRT, care must be taken to exclude, or to severely limit, the volume of normal tissue included in the high-dose region(s) (see Discussion).

Intraoperative Radiation Therapy
• IORT is a specialized technique that delivers a single, highly focused dose of radiation to a tumor bed at risk, or isolated unresectable residual, during an open surgical procedure. It is particularly useful in patients with recurrent disease within a previously radiated volume. During IORT, overlying normal tissue (such as bowel or other viscera) can be manually displaced from the region at risk. IORT is typically delivered with electrons using pre-formed applicators of variable sizes (matched to the surgically defined region at risk), which further constrain the area and depth of radiation exposure to avoid surrounding normal structures.
PRINCIPLES OF RADIATION THERAPY FOR CERVICAL CANCER


### CHEMOTHERAPY REGIMENS FOR RECURRENT OR METASTATIC CERVICAL CANCER†

*Strongly consider clinical trial*

<table>
<thead>
<tr>
<th>First-line combination therapy</th>
<th>Possible first-line single-agent therapy</th>
<th>Second-line therapy††</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Cisplatin/paclitaxel</em>¹,²</td>
<td>*Cisplatin (preferred as a single agent)*²</td>
<td><em>(Agents listed are category 2B unless otherwise noted)</em></td>
</tr>
<tr>
<td><em>Carboplatin/paclitaxel</em>³,⁴</td>
<td><em>Carboplatin</em>⁸</td>
<td><em>Bevacizumab</em></td>
</tr>
<tr>
<td><em>Cisplatin/topotecan</em>⁵</td>
<td><em>Paclitaxel</em>⁹</td>
<td><em>Docetaxel</em></td>
</tr>
<tr>
<td><em>Cisplatin/paclitaxel/bevacizumab</em>⁶</td>
<td></td>
<td><em>5-FU (5-fluorouracil)</em></td>
</tr>
<tr>
<td>*Cisplatin/gemcitabine (category 2B)*⁷</td>
<td></td>
<td><em>Gemcitabine</em></td>
</tr>
</tbody>
</table>

†Cisplatin, carboplatin, docetaxel, and paclitaxel may cause drug reactions [See NCCN Guidelines for Ovarian Cancer—Management of Drug Reactions (OV-C)].

††References for second-line therapy are provided in the Discussion.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
CHEMOTHERAPY REGIMENS FOR RECURRENT OR METASTATIC CERVICAL CANCER

(References)


Note: All recommendations are category 2A unless otherwise indicated. 
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### Table 1

<table>
<thead>
<tr>
<th>TNM Categories</th>
<th>FIGO Stages</th>
<th>Surgical-Pathologic Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td></td>
<td>Primary tumor cannot be assessed</td>
</tr>
<tr>
<td>T0</td>
<td></td>
<td>No evidence of primary tumor</td>
</tr>
<tr>
<td>Tis*</td>
<td></td>
<td>Carcinoma in situ (preinvasive carcinoma)</td>
</tr>
<tr>
<td>T1</td>
<td>I</td>
<td>Cervical carcinoma confined to cervix (extension to corpus should be disregarded)</td>
</tr>
<tr>
<td>T1a**</td>
<td>IA</td>
<td>Invasive carcinoma diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less. Vascular space involvement, venous or lymphatic, does not affect classification</td>
</tr>
<tr>
<td>T1a1</td>
<td>IA1</td>
<td>Measured stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread</td>
</tr>
<tr>
<td>T1a2</td>
<td>IA2</td>
<td>Measured stromal invasion more than 3.0 mm and not more than 5.0 mm with a horizontal spread 7.0 mm or less</td>
</tr>
<tr>
<td>T1b</td>
<td>IB</td>
<td>Clinically visible lesion confined to the cervix or microscopic lesion greater than T1a/IA2#</td>
</tr>
<tr>
<td>T1b1</td>
<td>IB1</td>
<td>Clinically visible lesion 4.0 cm or less in greatest dimension</td>
</tr>
<tr>
<td>T1b2</td>
<td>IB2</td>
<td>Clinically visible lesion more than 4.0 cm in greatest dimension</td>
</tr>
<tr>
<td>T2</td>
<td>II</td>
<td>Cervical carcinoma invades beyond uterus but not to pelvic wall or to lower third of vagina</td>
</tr>
<tr>
<td>T2a</td>
<td>IIA</td>
<td>Tumor without parametrial invasion</td>
</tr>
<tr>
<td>T2a1</td>
<td>IIA1</td>
<td>Clinically visible lesion 4.0 cm or less in greatest dimension</td>
</tr>
<tr>
<td>T2a2</td>
<td>IIA2</td>
<td>Clinically visible lesion more than 4.0 cm in greatest dimension</td>
</tr>
<tr>
<td>T2b</td>
<td>IIB</td>
<td>Tumor with parametrial invasion</td>
</tr>
<tr>
<td>T3</td>
<td>III</td>
<td>Tumor extends to pelvic wall and/or involves lower third of vagina and/or causes hydronephrosis or nonfunctioning kidney##</td>
</tr>
<tr>
<td>T3a</td>
<td>IIIA</td>
<td>Tumor involves lower third of vagina, no extension to pelvic wall</td>
</tr>
<tr>
<td>T3b</td>
<td>IIIB</td>
<td>Tumor extends to pelvic wall and/or causes hydronephrosis or nonfunctioning kidney</td>
</tr>
<tr>
<td>T4</td>
<td>IVA</td>
<td>Tumor invades mucosa of bladder or rectum, and/or extends beyond true pelvis (bullous edema is not sufficient to classify a tumor as T4)</td>
</tr>
<tr>
<td><strong>Note:</strong> FIGO no longer includes Stage 0 (Tis).</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Note:</strong> All macroscopically visible lesions—even with superficial invasion—are T1b/IB.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>#All macroscopically visible lesions—even with superficial invasion—are allotted to stage IB carcinomas. Invasion is limited to a measured stromal invasion with a maximal depth of 5.00 mm and a horizontal extension of not &gt;7.00 mm. Depth of invasion should not be &gt;5.00 mm taken from the base of the epithelium of the original tissue—superficial or glandular. The depth of invasion should always be reported in mm, even in those cases with &quot;early (minimal) stromal invasion&quot; (~1 mm). The involvement of vascular/lymphatic spaces should not change the stage allotment.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>##On rectal examination, there is no cancer-free space between the tumor and the pelvic wall. All cases with hydronephrosis or non-functioning kidney are included, unless they are known to be due to another cause.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.springer.com](http://www.springer.com).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC. Reprinted from: Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2009;105:103-104. Copyright 2009, with permission from International Federation of Gynecology and Obstetrics.*
## Staging—Cervical Cancer

**Table 1-Continued**  AJCC Tumor-Node-Metastases (TNM) and International Federation of Gynecology and Obstetrics (FIGO)

Surgical Staging Systems for Carcinoma of the Uterine Cervix

<table>
<thead>
<tr>
<th>Regional Lymph Nodes (N)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TNM Categories</td>
<td>FIGO Stages</td>
<td></td>
</tr>
<tr>
<td>NX</td>
<td>Regional lymph nodes cannot be assessed</td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>No regional lymph node metastasis</td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>Regional lymph node metastasis</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Distant Metastasis (M)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TNM Categories</td>
<td>FIGO Stages</td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
<td></td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis (including peritoneal spread, involvement of supraclavicular, mediastinal, or paraaortic lymph nodes, lung, liver, or bone)</td>
<td></td>
</tr>
</tbody>
</table>

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.springer.com](http://www.springer.com).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.

NCCN Guidelines Version 1.2014
Cervical Cancer

Discussion
This discussion is being updated to correspond with the newly updated algorithm. Last updated 10/25/12

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview ............................................................... MS-3
Diagnosis and Workup .......................................... MS-3
Staging ....................................................... .................................. MS-4
Primary Treatment ...................................................... MS-5
Clinical Trials and Basis for Treatment Selection .......... MS-5
Early-Stage Disease ................................................................. MS-6
Stage IA1 Disease ................................................................. MS-6
Fertility Sparing ................................................................. 6
Non–Fertility Sparing .......................................................... MS-6
Stage IA2 Disease ................................................................. MS-7
Fertility Sparing ............................................................... MS-7
Non–Fertility Sparing .......................................................... MS-7
Stage IB and IIA Disease ............................................................. MS-7
Stage IB1: Fertility Sparing .................................................... MS-7
Stage IB and IIA: Non–Fertility Sparing ................................ MS-7
Advanced Disease ............................................................ MS-8
Metastatic Disease ............................................................ MS-9
Adjuvant Treatment ........................................................... MS-9
Surveillance ................................................................. MS-10
Therapy for Relapse ........................................................... MS-11
Locoregional Therapy .......................................................... MS-11
Therapy for Metastatic Disease ................................................ MS-12
First-Line Combination Chemotherapy ......................... MS-12
Single Agents ................................................................. MS-13
Drug Reactions ................................................................. MS-13
Other Agents ................................................................. MS-14
Best Supportive Care ......................................................... MS-14
Incidental Cervical Cancer .............................................. MS-14
NCCN Guidelines Version 1.2014
Cervical Cancer

Radiation Therapy .................................................................MS-14

Radiation Treatment Planning .............................................MS-15

Normal Tissue Considerations ..............................................MS-16

Cervical Cancer and Pregnancy ............................................MS-16

Summary .................................................................................MS-17

Table 2: Estimates of the Relative Risk of Death in Five Clinical Trials of Concurrent Chemotherapy and Radiotherapy ..........MS-18

References .............................................................................MS-19
Overview

An estimated 12,200 new cases of carcinoma of the uterine cervix (ie, cervical cancer) will be diagnosed in the United States in 2012, and 4200 people will die of the disease.1 Cervical cancer rates are decreasing among women in the United States, although incidence remains high among Hispanic/Latino, Black, and Asian women.2,5 However, cervical cancer is a major world health problem for women. The global yearly incidence of cervical cancer for 2008 was 529,800; the annual death rate was 275,100.6 It is the third most common cancer in women worldwide,7,8 with 85% of cases occurring in developing countries, where cervical cancer is the second most frequent cause of cancer death in women.6

Persistent human papillomavirus (HPV) infection is the most important factor in the development of cervical cancer.9,10 The incidence of cervical cancer appears to be related to the prevalence of HPV in the population. In countries with a high incidence of cervical cancer, the prevalence of chronic HPV is approximately 10% to 20%, whereas the prevalence in low-incidence countries is 5% to 10%.7 Immunization against HPV prevents infection with certain types of HPV and, thus, is expected to prevent specific HPV cancer in women (see the NCCN Guidelines for Cervical Cancer Screening).11-15 Other epidemiologic risk factors associated with cervical cancer are a history of smoking, parity, contraceptive use, early age of onset of coitus, larger number of sexual partners, history of sexually transmitted disease, and chronic immunosuppression.16 Smoking cessation should be advised in current smokers, and abstinence should be encouraged in former smokers (http://smokefree.gov/).

Squamous cell carcinomas account for approximately 80% of all cervical cancers and adenocarcinoma accounts for approximately 20%.

In developed countries, the substantial decline in incidence and mortality of squamous cell carcinoma of the cervix is presumed to be the result of effective screening, although racial, ethnic, and geographic disparities exist.2,3,17,18 However, adenocarcinoma of the cervix has increased over the past 3 decades, probably because cervical cytologic screening methods are less effective for adenocarcinoma.19-22 Screening methods using HPV testing may increase detection of adenocarcinoma. Vaccination with HPV vaccines may also decrease the incidence of both squamous cell carcinoma and adenocarcinoma.21,23

By definition, the NCCN Guidelines cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment or individualization of treatments. “Many exceptions to the rule” were discussed among the members of the cervical cancer panel during the process of developing these guidelines.

Diagnosis and Workup

These NCCN Guidelines discuss squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix. Neuroendocrine carcinoma, small cell tumors, glassy-cell carcinomas, sarcomas, and other histologic types are not within the scope of these guidelines.

Currently, the International Federation of Gynecology and Obstetrics (FIGO) evaluation procedures for staging are limited to colposcopy, biopsy, conization of the cervix, cystoscopy, and proctosigmoidoscopy. More complex radiologic and surgical staging procedures are not addressed in the FIGO classification. In the United States, however, CT, MRI, combined PET-CT, and surgical staging are often used to guide treatment options and design.24-28
The earliest stages of cervical carcinoma may be asymptomatic or associated with a watery vaginal discharge and postcoital bleeding or intermittent spotting. Often these early symptoms are not recognized by the patient. Because of the accessibility of the uterine cervix, cervical cytology or Papanicolaou (Pap) smears and cervical biopsies can usually result in an accurate diagnosis (see the NCCN Guidelines for Cervical Cancer Screening). Cone biopsy (ie, conization) is recommended if the cervical biopsy is inadequate to define invasiveness or if accurate assessment of microinvasive disease is required. However, cervical cytologic screening methods are less useful for diagnosing adenocarcinoma, because adenocarcinoma in situ affects areas of the cervix that are harder to sample (ie, endocervical canal).\(^5\)\(^,\)\(^22\) The College of American Pathologists (CAP) protocol for cervical carcinoma is a useful guide (http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2012/Cervix_12protocol.pdf). This CAP protocol was revised in June 2012 and reflects recent updates in the AJCC/FIGO staging (ie, AJCC Cancer Staging Manual, 7th edition).

Workup for these patients with suspicious symptoms includes history and physical examination, CBC (including platelets), and liver and renal function tests. Recommended radiologic imaging includes chest radiograph, CT, or combined PET-CT, and MRI as indicated (eg, to rule out disease high in the endocervix).\(^25,\)\(^29\) However, imaging is optional for patients with stage IB1 or smaller tumors (see Workup in the NCCN Guidelines for Cervical Cancer). Cystoscopy and proctoscopy are only recommended if bladder or rectal extension is suspected.

Panel members discussed whether laparoscopic and robotic approaches should be recommended for staging and treatment. These techniques are being used more frequently, but long-term outcomes data are not yet available.\(^30\) Laparoscopic staging, lymphadenectomies, and radical hysterectomies can be performed satisfactorily and are used routinely in selected patients in several NCCN Member Institutions.\(^31,\)\(^34\) Data from studies overseas suggest that recurrence rates are low for laparoscopic radical hysterectomy after 3 to 6 years of follow-up.\(^35,\)\(^36\) Robotic radical hysterectomy (which is another minimally invasive surgical technique) is currently being performed for patients with early-stage cervical cancer. Potential advantages associated with laparoscopic and robotic approaches include decreased hospital stay and more rapid patient recovery.\(^37,\)\(^39\)

**Staging**

Because noninvasive radiographic imaging may not be routinely available in low-resource countries, the FIGO system limits the imaging to chest radiography, intravenous pyelography, and barium enema. The staging of carcinoma of the cervix is largely a clinical evaluation. Although surgical staging is more accurate than clinical staging, surgical staging often cannot be performed in low-resource countries.\(^27,\)\(^40,\)\(^41\) The panel currently uses the 2010 FIGO definitions and staging system (see Table 1).\(^40,\)\(^42\) This staging system from FIGO has been approved by the AJCC.\(^43\) With the 2010 staging, stage IIA is now subdivided into stage IIA1 (tumor size ≤4 cm) and stage IIA2 (tumor size >4 cm), which is the only change from the previous 1994 FIGO staging system.

Importantly, lymphovascular space invasion (LVSI) does not alter the FIGO classification.\(^40\) FIGO did not include LVSI, because pathologists do not always agree on whether LVSI is present in tissue samples. Some panel members believe that patients with stage IA1 who have extensive LVSI should be treated using stage 1B1 guidelines.

The use of MRI, CT, or combined PET-CT scans may aid in treatment planning but is not accepted for formal staging purposes.\(^27,\)\(^41,\)\(^44,\)\(^45\) In addition, FIGO has always maintained that staging is intended for
comparison purposes only and not as a guide for therapy. As a result, the panel uses the FIGO definitions as the stratification system for these guidelines, although the findings on imaging studies (ie, CT and MRI) are used to guide treatment options and design.\(^{29,46,47}\) MRI is useful to rule out disease high in the endocervix.

**Primary Treatment**

The primary treatment of early-stage cervical cancer is either surgery or radiation therapy (RT). Surgery is typically reserved for early-stage disease and smaller lesions, such as stage IA, IB1, and selected IIA1.\(^ {26}\) The panel agrees that concurrent chemoradiation is the primary treatment of choice for stages IB2 to IVA disease based on the results of 5 randomized clinical trials (see Table 2).\(^ {48,49}\) Chemoradiation can also be used for patients who are not candidates for hysterectomy. Although few studies have assessed treatment specifically for adenocarcinomas, they are typically treated in a similar manner to squamous cell carcinomas.\(^ {50-52}\)

Pelvic RT or chemoradiation will invariably lead to ovarian failure in premenopausal women.\(^ {53}\) To preserve intrinsic hormonal function, ovarian transposition may be considered before pelvic RT for select women younger than 45 years of age with squamous cell cancers.\(^ {54,55}\)

**Clinical Trials and Basis for Treatment Selection**

A randomized Italian study compared RT alone versus radical hysterectomy and lymph node dissection in patients with clinical early-stage disease (stage IB–IIA).\(^ {56}\) In surgical patients, adjuvant RT was given to those with parametrial extension, less than 3 cm of uninvolved cervical stroma, positive margins, or positive nodes. Identical outcomes were noted for patients treated with radiation versus surgery, with (or without) postoperative radiation, but higher complication rates were noted for the combined modality approach.

Concurrent chemoradiation, using cisplatin-based chemotherapy (either cisplatin alone or cisplatin/5-FU), is the treatment of choice for stages IB2, II, III, and IVA disease based on the results of 5 randomized clinical trials (see Table 2).\(^ {57-62}\) These 5 trials have shown that the use of concurrent chemoradiation results in a 30% to 50% decrease in the risk of death compared with RT alone. Although the optimal concurrent chemotherapy regimen to use with RT requires further investigation, these 5 trials clearly established a role for concurrent cisplatin-based chemoradiation. Based on these data, the NCI issued an alert stating that strong consideration should be given to using chemoradiation instead of RT alone for invasive cervical cancer (http://www.nih.gov/news/pr/feb99/nci-22.htm).\(^ {62}\) Long-term follow-up of 3 of these trials has confirmed that concurrent cisplatin-based chemoradiation improves progression-free survival (PFS) and overall survival when compared with RT with (or without) hydroxyurea.\(^ {63-65}\) A recent meta-analysis reported that chemoradiotherapy leads to a 6% improvement in 5-year survival (hazard ratio, 0.81; \(P < .001\)).\(^ {66}\) A large population-based registry analysis in Canada (n=4069) confirmed that chemoradiotherapy improved outcomes when compared with RT alone.\(^ {67}\)

Although chemoradiation is tolerated, acute and long-term side effects have been reported.\(^ {66,68-69}\) Some oncologists prefer concurrent single-agent cisplatin chemoradiation over cisplatin plus 5-FU chemoradiation, because the latter may be more toxic.\(^ {49,70}\) Concurrent carboplatin or nonplatinum chemoradiation regimens are options for patients who may not tolerate cisplatin-containing chemoradiation.\(^ {66,71-75}\) Note that when concurrent chemoradiation is used, the chemotherapy is typically given when the external-beam pelvic radiation is...
The panel believes that using “systemic consolidation” (ie, adding chemotherapy after chemoradiation) should only be used in clinical trials (eg, RTOG 0724, International OUTBACK trial [ANZGOG]).

Early-Stage Disease
After careful clinical evaluation and staging, the primary treatment of early-stage cervical cancer is either surgery or RT. The treatment schema is stratified using the FIGO staging system (see Table 1). A new fertility-sparing algorithm was added in 2012 for select patients with stage IA and IB1 disease (see Primary Treatment (Fertility Sparing) in the NCCN Guidelines for Cervical Cancer). Fertility-sparing surgery is generally not recommended for patients with small cell neuroendocrine tumors or those with minimal deviation adenocarcinoma because of a lack of data.

Stage IA1 Disease
Recommended options for stage IA1 depend on the results of cone biopsy and on whether patients 1) want to preserve their fertility; 2) are medically operable; and 3) have LVSI (see Primary Treatment (Fertility Sparing) and Primary Treatment (Non–Fertility Sparing) in the NCCN Guidelines for Cervical Cancer). The extent of the lymph node dissection depends on whether pelvic nodal disease and/or LVSI is present and the size of the tumors.

Fertility Sparing
For patients who desire fertility preservation, cone biopsy with or without pelvic lymph node dissection is recommended. For patients with negative margins after cone biopsy, observation is an option for select patients without LVSI if they desire fertility preservation. For patients with positive margins after cone biopsy, options include either a radical trachelectomy or a repeat cone biopsy. For patients with LVSI, radical trachelectomy and pelvic lymph node dissection is recommended with (or without) para-aortic lymph node sampling (category 2B for para-aortic lymph node sampling) (see Primary Treatment (Fertility Sparing) in the NCCN Guidelines for Cervical Cancer). Pelvic lymph node dissection is recommended for patients with LVSI who have negative margins after cone biopsy.

After childbearing is complete, hysterectomy can be considered for patients who have had either radical trachelectomy or a cone biopsy for early-stage disease if they have chronic persistent HPV infection, they have persistent abnormal Pap tests, or they desire this surgery. Note that trachelectomy (also known as cervicectomy) refers to removal of the cervix and upper vagina (ie, uterus remains intact).

A study found that among women attempting to conceive after radical trachelectomy for early-stage cervical cancer, the 5-year cumulative pregnancy rate was 52.8%; the cancer recurrence rate was low, but the miscarriage rate was higher. For young (<45 years) premenopausal women with early-stage squamous cell carcinoma who opt for ovarian preservation (ie, hysterectomy only), the rate of ovarian metastases is low.

Non–Fertility Sparing
For medically operable patients who do not desire fertility preservation, extrafascial (ie, simple or total) hysterectomy is commonly recommended for patients without LVSI and with either negative margins after cone biopsy or with positive margins for dysplasia. For patients with positive margins for carcinoma, modified radical hysterectomy is recommended with pelvic lymph node dissection (category 2B for node dissection) (see Primary Treatment (Non–Fertility Sparing) in the NCCN Guidelines for Cervical Cancer). If LVSI is present, then modified radical hysterectomy with lymph node dissection...
is recommended (category 2B for para-aortic lymph node sampling only). Para-aortic node dissection is indicated for patients with known or suspected pelvic nodal disease. For patients with negative margins after cone biopsy, observation is recommended for those who are medically inoperable or those who refuse surgery.

**Stage IA2 Disease**

**Fertility Sparing**
For patients who wish to preserve their fertility, radical trachelectomy and pelvic lymph node dissection with (or without) para-aortic lymph node sampling (category 2B for para-aortic node sampling) is recommended. Cone biopsy followed by observation is another option if the margins are negative and pelvic lymph node dissection is negative.

**Non–Fertility Sparing**
Recommended options for stage IA2 depend on whether patients want to preserve their fertility and whether they are medically operable. For medically operable patients who do not desire fertility preservation, recommended treatment includes either surgery or RT (see Primary Treatment (Non–Fertility Sparing) in the NCCN Guidelines for Cervical Cancer). The recommended surgical option is modified radical hysterectomy and pelvic lymph node dissection with (or without) para-aortic lymph node sampling (category 2B for para-aortic node sampling). Para-aortic node dissection is indicated for patients with known or suspected pelvic nodal disease.

Pelvic radiation with brachytherapy (total point A dose: 70–80 Gy) is a treatment option for patients who are medically inoperable or refuse surgery and do not desire fertility preservation. These doses are recommended for most patients based on summation of conventional external-beam fractionation and low–dose-rate (40–70 cGy/h) brachytherapy equivalents. Treatment should be modified based on normal tissue tolerance or on biologic equivalence calculations when using high–dose-rate brachytherapy (see also the Radiation Therapy section in this Discussion).

**Stage IB and IIA Disease**
Depending on their stage and disease bulk, patients with stage IB or IIA tumors can be treated with surgery, RT, or concurrent chemoradiation. Fertility-sparing surgery is only recommended for select patients with stage IB1 disease (see next section). A combined PET-CT scan can be performed to rule out extrapelvic disease before deciding how to treat these patients. The Gynecologic Oncology Group (GOG) considers that surgical staging is an option for patients with advanced cervical cancer. Radiologic imaging is recommended for assessing stage IB2 and IIA2 tumors.

**Stage IB1: Fertility Sparing**
For patients who desire fertility preservation, radical trachelectomy and pelvic lymph node dissection with (or without) para-aortic lymph node sampling is an option for stage IB1 disease, but typically only for tumors 2 cm or less (see Primary Treatment (Fertility Sparing) in the NCCN Guidelines for Cervical Cancer). Tumors that are 2 to 4 cm are left to the surgeon’s discretion. However, some surgeons suggest that a 2-cm cutoff may be used for vaginal trachelectomy, whereas a 4-cm cutoff may be used for abdominal (eg, laparoscopic, robotic) trachelectomy. In one study, oncologic outcomes were similar after 4 years when comparing radical trachelectomy with radical hysterectomy for patients with stage 1B1 cervical carcinoma.

**Stage IB and IIA: Non–Fertility Sparing**
The surgical option includes radical hysterectomy plus bilateral pelvic lymph node dissection with (or without) para-aortic lymph node...
Panel members feel that surgery is the most appropriate option for patients with stage IB1 or IIA1 disease, whereas concurrent chemoradiation is the most appropriate option for those with stage IB2 or IIA2 disease based on randomized trials. Thus, the surgical option is category 1 for patients with stage IB1 or IIA1 disease; however, surgery is category 2B for those with stage IB2 or IIA2 disease. Para-aortic node dissection may be performed for patients with larger tumors and suspected or known pelvic nodal disease. Some panel members feel that a pelvic lymph node dissection should be performed first and if negative, then the radical hysterectomy should be performed. If the lymph nodes are positive, then the hysterectomy should be abandoned; these patients should undergo chemoradiation.

Recent data suggest that sentinel lymph node biopsy may be useful for decreasing the need for pelvic lymphadenectomy in patients with early-stage cervical cancer. However, panel members believe the technique is not yet sufficiently validated for routine use. The role of sentinel lymph node biopsy continues to be evaluated in large prospective trials. For patients with stage IB or IIA tumors (including those who are not candidates for hysterectomy), another option is combined pelvic RT and brachytherapy with (or without) concurrent cisplatin-containing chemotherapy (see Primary Treatment (Non–Fertility Sparing) in the NCCN Guidelines for Cervical Cancer). This approach has not been specifically studied in patients with stage IB1 or IIA1 disease. Careful consideration of the risk/benefit ratio should be undertaken in these patients with smaller tumors.

For patients with clinical stage IB2 or IIA2 tumors who are treated with definitive radiation, concurrent cisplatin-containing chemotherapy has been shown to significantly improve patient survival. This recommendation has a category 1 recommendation (see Primary Treatment (Non–Fertility Sparing) in the NCCN Guidelines for Cervical Cancer).

For stage IB2 or IIA2 tumors, the panel had a major disagreement about recommending adjuvant hysterectomy (category 3) (also known as completion surgery) after primary chemoradiation. Adjuvant hysterectomy after RT has been shown to improve pelvic control, but not overall survival, and is associated with increased morbidity. Some clinicians feel that completion surgery may be considered in patients who have residual disease after concurrent chemoradiation but should not be performed if patients have a complete response. A recent study assessed completion hysterectomy in patients who had a complete response after concurrent chemoradiation, but the study was underpowered. The morbidity is higher after completion surgery, and it has not been shown to increase survival. However, the morbidity may be reduced if using completion laparoscopic hysterectomy after chemoradiation.

Advanced Disease

This category has traditionally included patients with stage IIB to IVA disease (ie, locally advanced disease). However, many oncolgists now include patients with IB2 and IIA2 disease in the advanced disease category. For patients with more advanced tumors who are undergoing primary chemoradiation, the volume of RT is critical and guided by assessment of nodal involvement in the pelvic and para-aortic nodes. Radiologic imaging studies (including PET-CT) are recommended for stage IB2 or greater disease. MRI is useful to rule out disease high in the endocervix. However, needle biopsy can be considered for questionable imaging findings. Surgical staging (ie, extraperitoneal or laparoscopic lymph node dissection) is also an option (category 2B) for
these patients. Surgical staging may also detect microscopic nodal disease that is not discernable with radiologic imaging.\textsuperscript{107}

For patients without nodal disease or with disease limited to the pelvis only through surgical staging, treatment consists of pelvic RT with concurrent cisplatin-based chemotherapy (category 1) and brachytherapy.\textsuperscript{48,49,58,60-62,108} Currently, acceptable concurrent cisplatin-based regimens include either weekly cisplatin or the combination of cisplatin/5-FU given every 3 to 4 weeks during RT.

A recent international phase III randomized trial reported that concurrent cisplatin/gemcitabine and RT followed by 2 additional cycles of cisplatin/gemcitabine after RT improved PFS and overall survival when compared with a standard regimen of concurrent cisplatin with pelvic RT.\textsuperscript{76} However, this trial is controversial because of changes in its statistical design and because the reported superior regimen of concurrent cisplatin/gemcitabine and RT has unresolved toxicity issues.\textsuperscript{76,109-111}

However, for patients with positive para-aortic and pelvic lymph nodes by imaging, extraperitoneal lymph node dissection should be considered followed by extended-field RT, concurrent cisplatin-containing chemotherapy, and brachytherapy (see Primary Treatment in the NCCN Guidelines for Cervical Cancer). Patients with positive para-aortic lymph nodes who are positive for distant metastases are treated with systemic chemotherapy (see Chemistry Regimens for Recurrent or Metastatic Cervical Cancer in the NCCN Guidelines) with (or without) individualized RT.\textsuperscript{112}

Metastatic Disease
For patients who present with distant metastatic disease (ie, stage IVB), primary treatment is often cisplatin-based chemotherapy (see Systemic Therapy for Metastatic Disease in this Discussion). In these situations, individualized RT may be considered for control of pelvic disease and other symptoms.\textsuperscript{112}

Adjuvant Treatment
Adjuvant treatment is indicated after radical hysterectomy depending on surgical findings and disease stage. Observation is appropriate for patients with stage IA2, IB1, or IIA1 disease who have negative nodes and no risk factors after radical hysterectomy. However, adjuvant treatment is indicated after radical hysterectomy if pathologic risk factors are discovered. Pelvic radiation is recommended (category 1) with (or without) concurrent cisplatin-based chemotherapy (category 2B for chemotherapy) for patients with stage IA2, IB1, or IIA1 disease who have negative lymph nodes after surgery but have large primary tumors, deep stromal invasion, and/or LVSI (see Adjuvant Treatment in the NCCN Guidelines for Cervical Cancer).\textsuperscript{113-117}

Adjuvant pelvic RT alone versus no further therapy was tested in a randomized trial (GOG 92) of selected patients with node-negative stage IB carcinoma of the cervix after hysterectomy and pelvic lymphadenectomy.\textsuperscript{117} Patients were considered to be “intermediate risk” and were eligible for this trial if they had at least 2 of the following risk factors: 1) greater than one-third stromal invasion; 2) capillary lymphatic space involvement; or 3) cervical tumor diameters more than 4 cm. Patients with positive lymph nodes or involved surgical margins were excluded. At 2 years, the recurrence-free rates were 88\% for adjuvant RT versus 79\% for the no-adjuvant-treatment group. After long-term follow-up (12 years), an updated analysis confirmed that adjuvant pelvic RT increased PFS; a clear trend towards improved overall survival was noted ($P=.07$).\textsuperscript{113} The role of concurrent cisplatin/RT in these
intermediate-risk patients is currently being evaluated in an international phase III randomized trial (GOG 263).

Postoperative pelvic radiation with concurrent cisplatin-containing chemotherapy (category 1)\(^5\) with (or without) vaginal brachytherapy is recommended for patients with positive pelvic nodes, positive surgical margin, and/or positive parametrium; these patients are considered to be “high risk” (see Adjuvant Treatment in the NCCN Guidelines for Cervical Cancer). Vaginal brachytherapy may be a useful boost for those with positive vaginal mucosal margins. Adjuvant concurrent chemoradiation significantly improves overall survival for these high-risk patients with early-stage disease (those with positive pelvic nodes, parametrial extension, and/or positive margins) who undergo radical hysterectomy and pelvic lymphadenectomy.\(^5\) The Intergroup trial 0107 showed a statistically significant benefit of adjuvant pelvic radiation with concurrent cisplatin and 5-FU in the treatment of patients with stage IA2, IB, or IIA disease who had positive lymph nodes, positive margins, and/or microscopic parametrial involvement found at surgery.\(^5\)

Depending on the results of primary surgery, imaging (chest CT or combined PET-CT scan) may be recommended to determine whether distant metastases are present. In women who are positive for distant metastases, biopsy of suspicious areas should be considered as indicated (see Adjuvant Treatment in the NCCN Guidelines for Cervical Cancer). For patients without distant metastases, recommended treatment is extended-field RT (including pelvic and para-aortic lymph nodes) with concurrent cisplatin-based chemotherapy and with (or without) brachytherapy. For patients with distant metastases, recommended treatment is systemic chemotherapy (see Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer in the NCCN Guidelines) with (or without) individualized RT.\(^\text{11}\)

Although neoadjuvant chemotherapy followed by surgery has been used in areas where RT is not available, data suggest no improvement in survival when compared with surgery alone for early-stage cervical cancer.\(^\text{11-12}\) The panel does not recommend the use of neoadjuvant chemotherapy.

**Surveillance**

The panel agrees with the new Society of Gynecologic Oncology’s recommendations for post-treatment surveillance.\(^\text{12}\) The recommended surveillance is based on the patient’s risk for recurrence and personal preferences. History and physical examination is recommended every 3 to 6 months for 2 years, every 6 to 12 months for another 3 to 5 years, and then annually (see Surveillance in the NCCN Guidelines for Cervical Cancer). High-risk patients can be assessed more frequently (eg, every 3 months for the first 2 years) than low-risk patients (eg, every 6 months).

Annual cervical/vaginal cytology tests can be considered as indicated for detection of lower genital tract dysplasia (eg, for those who have had fertility-sparing surgery). Some clinicians have suggested that rigorous cytology follow-up is not warranted because of studies stating that Pap smears did not detect recurrences in patients with stage I or II cervical cancer who were asymptomatic after treatment.\(^\text{121-123}\) It is important to emphasize good clinical evaluation and a high index of suspicion, because the detection rate of recurrent cervical cancer is low using cervical and vaginal cytology alone.\(^\text{12}\) Patient education regarding symptoms suggestive of recurrence is recommended (eg, vaginal discharge; weight loss; anorexia; pain in the pelvis, hips, back, or legs; persistent coughing). Smoking cessation and abstinence should be encouraged.\(^\text{12}\)
Imaging is not routinely recommended for surveillance but may be indicated in patients with symptoms or findings that are suspicious for recurrence.\textsuperscript{121,124,125} In patients at high risk for locoregional (central or para-aortic) failure, a combined PET-CT scan (eg, 3–6 months after treatment) or other radiologic imaging may be useful for detecting asymptomatic disease that is potentially curable.\textsuperscript{126-128} Many other tests remain optional based on clinical indications, such as semiannual CBCs, blood urea nitrogen, and serum creatinine determinations (see Surveillance in the NCCN Guidelines for Cervical Cancer). Patients with persistent or recurrent disease need to be evaluated using additional imaging studies as clinically indicated and surgical exploration in selected cases followed by therapy for relapse (see next section).\textsuperscript{129}

Patients treated with RT are prone to vaginal stenosis, which can impair sexual function. Anecdotal evidence suggests that vaginal dilators may be used to prevent or treat vaginal stenosis.\textsuperscript{130} Dilator use can start 2 to 4 weeks after RT is completed and can be performed indefinitely (http://www.mskcc.org/patient_education/assets/downloads-english/571.pdf).

Cervical cancer survivors are at risk for second cancers.\textsuperscript{131} Data suggest that patients who undergo RT for pelvic cancers are at risk for radiation-induced second cancers, especially at radiated sites near the cervix (eg, colon, rectum/anus, urinary bladder); therefore, careful surveillance is appropriate for these patients.\textsuperscript{132,133}

**Therapy for Relapse**

**Locoregional Therapy**

Patients with a localized recurrence of cervical cancer after initial treatment may be candidates for radical retreatment; options include 1) RT and/or chemotherapy, or 2) surgery.\textsuperscript{48,134} After treatment for relapse, long-term disease-free survival rates of approximately 40% have been reported in some situations.\textsuperscript{135}

For patients who experience locoregional recurrences who have not undergone previous RT or who experience recurrences outside of the previously treated RT field, therapy for relapse includes tumor-directed RT and platinum-based chemotherapy with (or without) brachytherapy; surgical resection can be considered if feasible (see Therapy for Relapse in the NCCN Guidelines for Cervical Cancer). Typically, the chemoradiation for recurrence uses cisplatin as a single agent or cisplatin plus 5-FU.\textsuperscript{136,137}

Patients with central pelvic recurrent disease after RT should be evaluated for pelvic exenteration, with (or without) intraoperative RT (IORT), although IORT is category 3.\textsuperscript{138-145} Surgical mortality is generally 5% or less, with survival rates approaching 50% in carefully selected patients.\textsuperscript{141} Concomitant measures with these radical procedures include adequate rehabilitation programs dealing with the psychosocial and psychosexual consequences of the surgery as well as reconstructive procedures.\textsuperscript{140,146-148} Although exenteration is the common surgical approach in postradiation patients with isolated central pelvic relapse, radical hysterectomy or brachytherapy may be an option in carefully selected patients with small central lesions (<2 cm).

For patients with noncentral recurrent disease, options include resection (with IORT for close or positive margins, category 3), tumor-directed RT with (or without) chemotherapy, chemotherapy, best supportive care (see the NCCN Guidelines for Palliative Care), or participation in a clinical trial. Patients who experience recurrence after second-line definitive therapy, either surgery or RT, have a poor prognosis. They can be treated with chemotherapy or best supportive care, or can be enrolled in a clinical trial.
Therapy for Metastatic Disease

Patients who develop distant metastases, either at initial presentation or at relapse, are rarely curable. For highly selected patients with isolated distant metastases, occasional long-term survival has been reported with either 1) surgical resection with (or without) IORT (IORT is category 3); or 2) RT with (or without) concurrent chemotherapy (see Therapy for Relapse in the NCCN Guidelines for Cervical Cancer). For example, patients who may benefit from aggressive local therapy for oligometastatic disease include those with lung, liver, or bone metastases. For most other patients with distant metastases, appropriate treatment is either chemotherapy (see Chemotherapy Regimens for Recurrent or Metastatic Cervical Cancer in the NCCN Guidelines for Cervical Cancer) or best supportive care.

The palliation of pelvic recurrences in heavily irradiated sites that are not amenable to local pain control techniques or to surgical resection is difficult. These sites are generally not responsive to chemotherapy. Adequately palliating the complications of pain and fistulae from these recurrences is clinically challenging (http://emedicine.medscape.com/article/270646-overview). However, short courses of RT may provide symptomatic relief to patients with bone metastases, painful para-aortic nodes, or supraclavicular adenopathy.\(^{112,149,150}\)

Chemotherapy is often recommended for patients with extrapelvic metastases or recurrent disease who are not candidates for RT or exenterative surgery. Patients who respond to chemotherapy may have relief from pain and other symptoms. If cisplatin was previously used as a radiosensitizer, combination platinum-based regimens are preferred over single agents in the metastatic disease setting based on several randomized phase III trials (see next paragraph).\(^{151,152}\) However, responses to chemotherapy are often of short duration and survival is rarely increased.

First-Line Combination Chemotherapy

Cisplatin has been considered the most effective agent for metastatic cervical cancer.\(^{153}\) However, most patients who develop metastatic disease have received concurrent cisplatin/RT as primary treatment and may no longer be sensitive to single-agent platinum therapy.\(^{151,152}\) Cisplatin-based combination chemotherapy regimens, such as cisplatin/paclitaxel and cisplatin/topotecan, have been extensively investigated in clinical studies.\(^{151,152,154-156}\)

A randomized phase III study (GOG 169) in 264 patients compared cisplatin/paclitaxel versus cisplatin alone for metastatic, recurrent, or persistent cervical cancer. Patients receiving the 2-drug combination had a higher response rate (36% vs. 19%) and improved PFS (4.8 vs. 2.8 months; \(P > .001\)) compared to single-agent cisplatin, although no improvement was seen in median survival.\(^{151}\) Patients who responded to cisplatin/paclitaxel had a significant improvement in quality of life. Preliminary data from a phase III randomized trial suggest that carboplatin/paclitaxel is equivalent to cisplatin/paclitaxel in women with metastatic or recurrent cervical cancer.\(^{157,158}\) Many physicians use carboplatin/paclitaxel because of ease of administration and tolerability.\(^{159}\)

Another randomized phase III study (GOG 179) in 294 patients investigated cisplatin/topotecan versus cisplatin alone for recurrent or persistent cervical cancer. The topotecan combination regimen was shown to be superior to single-agent cisplatin with respect to overall response rate (27% vs. 13%, \(P = .004\)), PFS (4.6 vs. 2.9 months; \(P = .014\)), and median survival (9.4 vs. 6.5 months; \(P = .017\)).\(^{152}\) The FDA has approved cisplatin/topotecan for advanced cervical cancer.
However, the cisplatin/paclitaxel or carboplatin/paclitaxel regimens are less toxic and easier to administer than cisplatin/topotecan.

A recent phase III trial (GOG 204) in 513 patients with advanced metastatic or recurrent cancer compared 4 cisplatin-doublet regimens (cisplatin/paclitaxel, cisplatin/topotecan, cisplatin/gemcitabine, and cisplatin/vinorelbine).\textsuperscript{156} The trial was closed early based on futility analysis, because it was apparent that the cisplatin/topotecan, cisplatin/gemcitabine, and cisplatin/vinorelbine regimens were not superior to the control arm of cisplatin/paclitaxel. No significant differences in overall survival were seen; however, the trends for response rate, PFS, and overall survival (12.9 vs. 10 months) suggest that cisplatin/paclitaxel is superior to the other regimens. Cisplatin/paclitaxel was associated with less thrombocytopenia and anemia (but with more nausea, vomiting, infection, and alopecia) than the other regimens.

Based on the previous studies, cisplatin/paclitaxel and carboplatin/paclitaxel have become the most widely used systemic regimens for metastatic or recurrent cervical cancer.\textsuperscript{151,156,157} However, for patients who may not be candidates for taxanes, cisplatin/topotecan and cisplatin/gemcitabine remain reasonable alternative regimens.\textsuperscript{76,152} Nonplatinum regimens are also being studied and may be considered in patients who cannot tolerate platinum-based chemotherapy.\textsuperscript{160}

**Single Agents**

Cisplatin is generally regarded as the most active agent and is recommended as a possible first-line single-agent chemotherapy in recurrent or metastatic cervical cancer; reported response rates are approximately 20\% to 30\%, with an occasional complete response.\textsuperscript{151,153,161,162} Overall survival with cisplatin is approximately 6 to 9 months. Both carboplatin and paclitaxel have each been reported to be tolerable and efficacious and are also possible first-line single-agent chemotherapy.\textsuperscript{163-166} Therefore, palliation with single agents—cisplatin, carboplatin, or paclitaxel—is a reasonable approach in patients with recurrent disease not amenable to surgical or radiotherapeutic approaches.

Other agents (that are category 2B unless otherwise indicated) that have shown responses or prolongation of PFS and may be useful as second-line therapy include bevacizumab,\textsuperscript{167} docetaxel,\textsuperscript{168} 5-FU,\textsuperscript{169} gemcitabine,\textsuperscript{170} ifosfamide,\textsuperscript{171,172} irinotecan,\textsuperscript{173} mitomycin,\textsuperscript{174} topotecan,\textsuperscript{175,176} pemetrexed (category 3),\textsuperscript{177} and vinorelbine (category 3).\textsuperscript{178}

**Drug Reactions**

Virtually all drugs have the potential to cause adverse reactions, either during or after infusion.\textsuperscript{179} In cervical cancer treatment, drugs that more commonly cause adverse reactions include carboplatin, cisplatin, docetaxel, liposomal doxorubicin, and paclitaxel. Most of these drug reactions are mild infusion reactions (ie, skin reactions, cardiovascular reactions, respiratory or throat tightness), but more severe allergic reactions (ie, life-threatening anaphylaxis) can occur.\textsuperscript{180,181} In addition, patients can have severe infusion reactions and mild allergic reactions. Infusion reactions are more common with paclitaxel.\textsuperscript{182} Allergic reactions (ie, true drug allergies) are more common with platinum agents (ie, carboplatin, cisplatin).\textsuperscript{182,183}

Management of drug reactions is discussed in the NCCN Guidelines for Ovarian Cancer.\textsuperscript{182} Importantly, patients who have had severe life-threatening reactions should not receive the implicated agent again unless evaluated by an allergist or specialist in drug desensitization. If a mild allergic reaction previously occurred and it is appropriate to administer the drug again, a desensitization regimen is recommended.
even if the symptoms have resolved. Various desensitization regimens have been published and should be followed. Patients must be desensitized with each infusion if they have had a previous reaction. Almost all patients can be desensitized. To maximize safety, patients should be desensitized in the intensive care unit.

**Other Agents**
Vaccine therapies currently have no established role in the treatment of cervical cancer at the present time, except in the setting of a clinical trial. Targeted therapy (using small molecules or monoclonal antibodies) is currently used in clinical trials.

**Best Supportive Care**
Patients with refractory systemic cancer warrant a comprehensive coordinated approach involving hospice care, pain consultants, and emotional and spiritual support, individualized to the situation (see the NCCN Guidelines for Palliative Care).

**Incidental Cervical Cancer**
Invasive cervical carcinoma is sometimes found incidentally after extrafascial hysterectomy. Workup for these patients includes history and physical examination, CBC (including platelets), and liver and renal function tests. Recommended radiologic imaging includes chest radiography, CT, or combined PET-CT; MRI may be performed if indicated to rule out gross residual disease. However, imaging is optional for patients with stage IB1 or smaller tumors (see **Incidental Finding of Invasive Cervical Cancer at Simple Hysterectomy** in the NCCN Guidelines for Cervical Cancer).

No definitive data are available to guide the appropriate adjuvant treatment of these patients. Surveillance is recommended for patients with stage 1A1 cervical cancer who do not have LVSI. For patients with either stage IA1 with LVSI or with stage 1A2 or higher tumors (pathologic findings), the panel believes that a reasonable treatment schema should be based on the status of the surgical margins. If margins are positive and imaging is negative for nodal disease, then pelvic RT with concurrent cisplatin-containing chemotherapy with (or without) individualized brachytherapy is recommended (see **Primary Treatment** in the NCCN Guidelines for Cervical Cancer).

If margins or imaging is negative in stage 1A2 or greater tumors, options include: 1) pelvic RT with (or without) concurrent cisplatin-containing chemotherapy and brachytherapy; or 2) a complete parametrectomy, upper vaginectomy, and pelvic lymph node dissection with (or without) para-aortic lymph node sampling. Typically, observation is recommended for patients with negative lymph nodes. However, pelvic radiation with (or without) vaginal brachytherapy is an option if they have high-risk factors (ie, large primary tumor, deep stromal invasion, LVSI) (see **Primary Treatment** in the NCCN Guidelines for Cervical Cancer). Concurrent cisplatin-based chemoradiation is recommended for gross residual disease, positive imaging, disease in the lymph nodes and/or parametrium, and/or a positive surgical margin; individualized brachytherapy is clearly indicated for a positive vaginal margin.

**Radiation Therapy**
RT is often used in the management of patients with cervical cancer either 1) as definitive therapy for those with locally advanced disease or for those who are poor surgical candidates; or 2) as adjuvant therapy following radical hysterectomy for those who have one or more pathologic risk factors (eg, positive lymph nodes, parametrial infiltration, positive surgical margins, large tumor size, deep stromal invasion, LVSI).
The algorithm provides general RT dosage recommendations, which are expanded in the Principles of Radiation Therapy (see the NCCN Guidelines for Cervical Cancer). These RT dosages should not be interpreted as stand-alone recommendations, because RT techniques and clinical judgment are an essential part of developing an appropriate treatment regimen.

Optimum staging of patients to precisely delineate the primary tumor volume and draining lymph nodes, including abdominopelvic radiologic studies (CT, MRI, or combined PET-CT scans), is recommended in patients with stage IB2, IIA2, or advanced-stage tumors. Contemporary imaging studies must be correlated with careful assessment of clinical findings to define tumor extent, especially with regard to vaginal or parametrial extension.

Radiation Treatment Planning

Technologic advances in imaging, computer treatment planning systems, and linear accelerator technology have enabled the more precise delivery radiation doses to the pelvis. However, physical accuracy of dose delivery must be matched to a clear understanding of tumor extent, potential pathways of spread, and historical patterns of locoregional recurrence to avoid geographic misses.

CT-based treatment planning with conformal blocking and dosimetry is considered standard care for external-beam RT. Brachytherapy is a critical component of definitive therapy in patients with cervical cancer who are not candidates for surgery (ie, those with an intact cervix); it may also be used as adjuvant therapy. Brachytherapy is typically combined with external-beam radiation in an integrated treatment plan.

For patients with locally advanced cancers, initial radiation treatment of 40 to 45 Gy to the whole pelvis is often necessary to obtain tumor shrinkage to permit optimal intracavitary placements. With low-dose-rate intracavitary systems, total doses from brachytherapy and external-beam radiation to point A of at least 80 Gy are currently recommended for small tumors, with doses of 85 Gy or higher recommended for larger tumors (http://www.americanbrachytherapy.org/guidelines/cervical_cancer_task_group.pdf).

For lesions in the lower one third of the vagina, the inguinal lymph nodes must be treated. The use of extended-field radiation to treat occult or macroscopic para-aortic lymph node disease must be carefully planned to ensure an adequate dose (45 Gy for microscopic disease) without exceeding bowel, spinal cord, or renal tolerances. General recommendations for radiation volumes and doses are discussed in the algorithm (see Principles of Radiation Therapy for Cervical Cancer in the NCCN Guidelines for Cervical Cancer).

Intensity-modulated RT (IMRT) is becoming more widely available; however, issues regarding target definition, patient and target immobilization, tissue deformation, and reproducibility remain to be validated. The role of IMRT in cervical cancer continues to be evaluated in several prospective multicenter clinical trials.

Several retrospective analyses suggest that prolonged treatment duration has an adverse effect on outcome. Extending the overall treatment beyond 6 to 8 weeks can result in approximately a 0.5% to 1% decrease in pelvic control and cause specific survival for each extra day of overall treatment time. Thus, although no prospective randomized trials have been performed, it is generally accepted that the entire RT course (including both external-beam RT and brachytherapy components) should be completed in a timely fashion (within 8 weeks);
delays or splits in the radiation treatment should be avoided whenever possible.

Normal Tissue Considerations
Planning for RT in cervical cancer must take into account the potential impact on surrounding critical structures, such as rectum, bladder, sigmoid, small bowel, and bone. Acute effects (ie, diarrhea, bladder irritation, fatigue) occur to some degree in most patients undergoing radiation and are typically magnified by concurrent chemotherapy. However, acute effects can often be managed with medications and supportive care, and they generally resolve soon after completion of radiation. To avoid treatment-related menopause, ovarian transposition can be considered before pelvic RT in select young patients (<45 years with early-stage disease).53-55

After therapy for cervical cancer, late side effects may include potential injury to bladder, rectum, bowel, and pelvic skeletal structures.395 The risk of major complications (ie, obstruction, fibrosis/necrosis, fistula) is related to the volume, total dose, dose per fraction, and specific intrinsic radiosensitivity of the normal tissue that is irradiated.191,206 Careful blocking to minimize normal tissue exposure while not compromising tumor coverage is critical to achieving optimal outcomes. In addition, patient-related conditions (ie, inflammatory bowel disease, collagen-vascular disease, multiple abdominal/pelvic surgeries, history of pelvic inflammatory disease, diabetes) influence determination of radiation dose and volumes.

For most patients, it is generally accepted that the whole pelvis can tolerate an external-beam radiation dose of 40 to 50 Gy. Gross disease in the parametria or unresected nodes may be treated with tightly contoured external-beam boosts to 60 to 65 Gy. Intracavitary brachytherapy boosts require attention to proper placement of the applicators within the uterus and against the cervix and vaginal apex, as well as appropriate packing to maximally displace the bladder and rectum.

Cervical Cancer and Pregnancy
Cervical cancer is the most frequently diagnosed gynecologic malignancy in pregnant women; however, most women have stage I disease.207-210 Invasive cervical cancer during pregnancy creates a clinical dilemma and requires multidisciplinary care.207,211 Women must make the difficult decision either to delay treatment until documented fetal maturity or to undergo immediate treatment based on their stage of disease.208,211 Women who delay treatment until fetal maturity should have their children delivered by cesarean section.210,212,213 Vaginal radical trachelectomy has been successfully performed in a few pregnant patients with early-stage cervical cancer.214-217

Patients with early-stage disease may prefer to have radical hysterectomy and node dissection instead of RT to avoid radiation fibrosis and to preserve their ovaries. Patients with early-stage disease who delay treatment until fetal maturity can undergo cesarean section with concurrent radical hysterectomy and pelvic node dissection. For those choosing RT, traditional RT with (or without) chemotherapy protocols (described previously) may need to be modified.210
Summary

Cervical cancer is decreasing in the United States because of the wide use of screening; however, it is increasing in developing countries (~275,000 deaths/year), because screening is not available to many women. Effective treatment for cervical cancer (including surgery and concurrent chemoradiation) can yield cures in 80% of women with early-stage disease (stages I–II) and in 60% of women with stage III disease. The hope is that immunization against HPV (using vaccines) will prevent persistent infection with certain types of the virus and will therefore prevent specific HPV cancer in women.14,15,218
### Table 2: Estimates of the Relative Risk of Death in Five Clinical Trials of Concurrent Chemotherapy and Radiotherapy

<table>
<thead>
<tr>
<th>Study*</th>
<th>FIGO Stage</th>
<th>Control Group</th>
<th>Comparison Group</th>
<th>Relative Risk of Death in Comparison Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keys et al.†</td>
<td>IB2</td>
<td>Radiotherapy</td>
<td>Radiotherapy plus weekly cisplatin</td>
<td>0.54</td>
</tr>
<tr>
<td>Rose, Bundy, Watkins et al.†</td>
<td>IIB-IVA</td>
<td>Radiotherapy plus hydroxyurea</td>
<td>Radiotherapy plus weekly cisplatin</td>
<td>0.61</td>
</tr>
<tr>
<td>Morris et al.†</td>
<td>IB2-IVA</td>
<td>Extended-field radiotherapy</td>
<td>Radiotherapy plus cisplatin and fluorouracil</td>
<td>0.52</td>
</tr>
<tr>
<td>Whitney et al.</td>
<td>IIB-IVA</td>
<td>Radiotherapy plus hydroxyurea</td>
<td>Radiotherapy plus cisplatin and fluorouracil</td>
<td>0.72</td>
</tr>
<tr>
<td>Peters et al.</td>
<td>IB or IIA (selected postoperatively)</td>
<td>Radiotherapy</td>
<td>Radiotherapy plus cisplatin and fluorouracil</td>
<td>0.50</td>
</tr>
</tbody>
</table>

**Abbreviation:** FIGO, International Federation of Gynecology and Obstetrics.

*See Discussion for all references.

†These studies have been updated (see Discussion).

Used with permission from Thomas GM. Improved treatment for cervical cancer concurrent chemotherapy and radiotherapy. N Engl J Med 1999;340(15):1198-1200. Copyright© 1999 Massachusetts Medical Society. All rights reserved.
References


73. Higgins RV, Naumann WR, Hall JB, Haake M. Concurrent carboplatin with pelvic radiation therapy in the primary treatment of...


158. Saito I, Kitagawa R, Fukuda H, et al. A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent...


185. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.


